U.S. patent application number 13/224847 was filed with the patent office on 2012-08-09 for methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines.
This patent application is currently assigned to GlycoMimetics, Inc.. Invention is credited to John L. MAGNANI.
Application Number | 20120202762 13/224847 |
Document ID | / |
Family ID | 39357997 |
Filed Date | 2012-08-09 |
United States Patent
Application |
20120202762 |
Kind Code |
A1 |
MAGNANI; John L. |
August 9, 2012 |
METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND
N-ACETYL HEXOSAMINES
Abstract
Methods are provided for using a compound to treat, for example,
endothelial dysfunction including vascular abnormalities. More
specifically, methods are described for using an oligosaccharide
compound or glycomimetic compound wherein a cyclohexane derivative
is incorporated in either.
Inventors: |
MAGNANI; John L.;
(Gaithersburg, MD) |
Assignee: |
GlycoMimetics, Inc.
Gaithersburg
MD
|
Family ID: |
39357997 |
Appl. No.: |
13/224847 |
Filed: |
September 2, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12069436 |
Feb 7, 2008 |
8026222 |
|
|
13224847 |
|
|
|
|
60900398 |
Feb 9, 2007 |
|
|
|
60932779 |
May 31, 2007 |
|
|
|
Current U.S.
Class: |
514/35 |
Current CPC
Class: |
A61P 7/00 20180101; A61P
9/14 20180101; A61P 35/00 20180101; A61P 7/06 20180101; A61P 37/06
20180101; A61P 3/10 20180101; A61P 17/06 20180101; A61P 37/02
20180101; A61P 17/00 20180101; A61K 31/7032 20130101; A61P 29/00
20180101; A61P 31/06 20180101; A61P 9/00 20180101; A61P 9/10
20180101; A61P 17/04 20180101 |
Class at
Publication: |
514/35 |
International
Class: |
A61K 31/7034 20060101
A61K031/7034; A61P 17/06 20060101 A61P017/06; A61P 35/00 20060101
A61P035/00; A61P 17/00 20060101 A61P017/00; A61P 9/14 20060101
A61P009/14; A61P 37/06 20060101 A61P037/06 |
Claims
1. A method for treating an endothelial dysfunction comprising
administering to an individual in need thereof in an amount
effective to treat the endothelial dysfunction an oligosaccharide
or glycomimetic compound that contains at least one cyclohexane
derivative, wherein the cyclohexane derivative has the formula:
##STR00104## wherein, R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
2. The method according to claim 1 wherein the compound comprises:
##STR00105## wherein, R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2)--NH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; R.sup.3=--OH, ##STR00106## --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, ##STR00107##
where Q is H or a physiologically acceptable salt, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl,
heteroaryl, (CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl
where m is 1-10, and where n=0-10, and any of the above ring
compounds may be substituted with one to three independently
selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy, NO.sub.2,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, or C.sub.1-C.sub.14 aryl;
R.sup.4= ##STR00108## 6' sulfated GlcNAc, 6' carboxylated GlcNAc,
6' sulfated GalNAc, 6' sulfated galactose, 6' carboxylated
galactose, ##STR00109## where Q is H or a physiologically
acceptable salt or C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl,
(CH.sub.2).sub.n-aryl or (CH.sub.2).sub.n-heteroaryl where n is
1-10, and where R.sup.9 is aryl, heteroaryl, cyclohexane, t-butane,
adamantane, or triazole, and any of R.sup.9 may be substituted with
one to three independently selected of Cl, F, CF.sub.3,
C.sub.1-C.sub.8 alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY,
C(.dbd.O)OY, NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or
C.sub.1-C.sub.14 aryl; or ##STR00110## where R.sup.10 is one of
##STR00111## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, n=1-4, Z and
Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
and heteroaryl substituted with Me, OMe, halide, OH; and
R.sup.5.dbd.H, D-mannose, L-galactose, D-arabinose, L-fucose,
polyols ##STR00112## where X.dbd.CF.sub.3, cyclopropyl or phenyl,
or ##STR00113## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where R.sup.11 is
aryl, heteroaryl, ##STR00114## where Q is H or a physiologically
acceptable salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
3. The method according to claim 1 wherein the compound consists of
the compound of claim 2.
4. The method according to claim 1 wherein the compound has the
formula: ##STR00115## where Q is H or a physiologically acceptable
salt, and Me is methyl.
5. The method according to claim 1 wherein the compound has the
formula: ##STR00116## where Q is H or a physiologically acceptable
salt, Me is methyl and Bz is benzoyl.
6. The method according to claim 1 wherein the compound has the
formula: ##STR00117## where Q is H or a physiologically acceptable
salt, Me is methyl and Bz is benzoyl.
7. The method according to claim 1 wherein the compound has the
formula: ##STR00118## where Q is H or a physiologically acceptable
salt, Me is methyl and Bz is benzoyl.
8. The method according to claim 1 wherein the compound has the
formula: ##STR00119## where Q is H or a physiologically acceptable
salt, and Me is methyl.
9. The method according to claim 1 wherein the compound has the
formula: ##STR00120## where Q is H or a physiologically acceptable
salt, Me is methyl and Bz is benzoyl.
10. The method according to claim 1 wherein the compound has the
formula: ##STR00121## where Me is methyl.
11. The method according to claim 1 wherein the compound has the
formula: ##STR00122## where Q is H or a physiologically acceptable
salt, Me is methyl and Bz is benzoyl.
12. The method according to claim 1 wherein the compound has the
formula: ##STR00123## where Q is H or a physiologically acceptable
salt, and Me is methyl.
13. The method according to claim 1 wherein the compound has the
formula: ##STR00124## where Q is H or a physiologically acceptable
salt, Me is methyl and Bz is benzoyl.
14. The method according to claim 1 wherein the compound has the
formula: ##STR00125## where Q is H or a physiologically acceptable
salt, and Me is methyl.
15. The method according to claim 1 wherein the compound has the
formula: ##STR00126## where Q is H or a physiologically acceptable
salt, Me is methyl and Bz is benzoyl.
16. The method according to claim 1 wherein the compound has the
formula: ##STR00127## where Me is methyl, Et is ethyl and Bz is
benzoyl.
17. The method according to claim 1 wherein the compound has the
formula: ##STR00128## where Me is methyl and Bz is benzoyl.
18. The method according to claim 1 wherein the compound has the
formula: ##STR00129## where Me is methyl, Et is ethyl and Bz is
benzoyl.
19. The method according to claim 1 wherein the compound has the
formula: ##STR00130## where Me is methyl and Bz is benzoyl.
20. The method according to claim 1 wherein the compound has a
polyethylene glycol attached thereto.
21. The method according to claim 1 wherein the compound is
attached by polyethylene glycol to another of the compound.
22. The method according to claim 1 wherein the endothelial
dysfunction is a vascular abnormality.
23. The method according to claim 22 wherein the vascular
abnormality is associated with diabetes.
24. The method according to claim 22 wherein the vascular
abnormality is associated with sickle cell disease.
25. The method according to claim 22 wherein the vascular
abnormality is associated with atherosclerosis.
26. The method according to claim 25 wherein the individual is also
being treated with aspirin or an aspirin substitute useful for
atherosclerosis.
27. A method for treating graft vs. host disease comprising
administering to an individual in need thereof in an amount
effective to treat graft vs. host disease an oligosaccharide or
glycomimetic compound that contains at least one cyclohexane
derivative wherein the cyclohexane derivative has the formula:
##STR00131## wherein, R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
28. The method according to claim 27 wherein the compound
comprises: ##STR00132## wherein, R.sup.1.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl
substituted with C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted
with C(.dbd.O)NHX, where X.dbd.C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; O(.dbd.O)X,
OX, NHX, NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH;
R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, OH, or NHX where X.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2)--NH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; ##STR00133## --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, ##STR00134##
where Q is H or a physiologically acceptable salt, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl,
heteroaryl, (CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl
where m is 1-10, and where n=0-10, and any of the above ring
compounds may be substituted with one to three independently
selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy, NO.sub.2,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, or C.sub.1-C.sub.14 aryl;
##STR00135## 6' sulfated GlcNAc, 6' carboxylated GlcNAc, 6'
sulfated GalNAc, 6' sulfated galactose, 6' carboxylated galactose,
##STR00136## where Q is H or a physiologically acceptable salt or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.n-aryl or
(CH.sub.2).sub.n-heteroaryl where n is 1-10, and where R.sup.9 is
aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole,
and any of R.sup.9 may be substituted with one to three
independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy,
NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl or C.sub.1-C.sub.14 aryl; or
##STR00137## where R.sup.10 is one of ##STR00138## where Q is H or
a physiologically acceptable salt, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl,
(CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl where m is
1-10, n=1-4, Z and Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH;
and R.sup.5.dbd.H, D-mannose, L-galactose, D-arabinose, L-fucose,
polyols ##STR00139## where X.dbd.CF.sub.3, cyclopropyl or phenyl,
or ##STR00140## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where R.sup.11 is
aryl, heteroaryl, ##STR00141## where Q is H or a physiologically
acceptable salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
29. The method according to claim 27 wherein the compound consists
of the compound of claim 28.
30. A method for treating cutaneous T-cell lymphoma comprising
administering to an individual in need thereof in an amount
effective to treat cutaneous T-cell lymphoma an oligosaccharide or
glycomimetic compound that contains at least one cyclohexane
derivative wherein the cyclohexane derivative has the formula:
##STR00142## wherein, R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
31. The method according to claim 30 wherein the compound
comprises: ##STR00143## wherein, R.sup.1.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl
substituted with C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted
with C(.dbd.O)NHX, where X.dbd.C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; O(.dbd.O)X,
OX, NHX, NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH;
R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, OH, or NHX where X.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; ##STR00144## --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, ##STR00145##
where Q is H or a physiologically acceptable salt, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl,
heteroaryl, (CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl
where m is 1-10, and where n=0-10, and any of the above ring
compounds may be substituted with one to three independently
selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy, NO.sub.2,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, or C.sub.1-C.sub.14 aryl;
##STR00146## 6' sulfated GlcNAc, 6' carboxylated GlcNAc, 6'
sulfated GalNAc, 6' sulfated galactose, 6' carboxylated galactose,
##STR00147## where Q is H or a physiologically acceptable salt or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.n-aryl or
(CH.sub.2).sub.n-heteroaryl where n is 1-10, and where R.sup.9 is
aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole,
and any of R.sup.9 may be substituted with one to three
independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy,
NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl or C.sub.1-C.sub.14 aryl; or
##STR00148## where R.sup.10 is one of ##STR00149## where Q is H or
a physiologically acceptable salt, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl,
(CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl where m is
1-10, n=1-4, Z and Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH;
and R.sup.5.dbd.H, D-mannose, L-galactose, D-arabinose, L-fucose,
polyols ##STR00150## where X.dbd.CF.sub.3, cyclopropyl or phenyl,
or ##STR00151## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkaanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where R.sup.11 is
aryl, heteroaryl, ##STR00152## where Q is H or a physiologically
acceptable salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
32. The method according to claim 30 wherein the compound consists
of the compound of claim 31.
33. A method for treating disease involving inflammatory cells in
the skin comprising administering to an individual in need thereof
in an amount effective to treat disease involving inflammatory
cells in the skin an oligosaccharide or glycomimetic compound that
contains at least one cyclohexane derivative wherein the
cyclohexane derivative has the formula: ##STR00153## wherein,
R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, OH, or NHX where X.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; C(.dbd.O)OX, alkanyl substituted with C(.dbd.O)OX,
C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX, where
X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
34. The method according to claim 33 wherein the compound
comprises: ##STR00154## wherein, R.sup.1.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl
substituted with C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted
with C(.dbd.O)NHX, where X.dbd.C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; O(.dbd.O)X,
OX, NHX, NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH;
R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, OH, or NHX where X.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H; ##STR00155## R.sup.3=--OH, --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, ##STR00156##
where Q is H or a physiologically acceptable salt, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl,
heteroaryl, (CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl
where m is 1-10, and where n=0-10, and any of the above ring
compounds may be substituted with one to three independently
selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy, NO.sub.2,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, or C.sub.1-C.sub.14 aryl;
R.sup.4= ##STR00157## 6' sulfated GlcNAc, 6' carboxylated GlcNAc,
6' sulfated GalNAc, 6' sulfated galactose, 6' carboxylated
galactose, ##STR00158## where Q is H or a physiologically
acceptable salt or C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl,
(CH.sub.2).sub.n-aryl or (CH.sub.2).sub.n-heteroaryl where n is
1-10, and where R.sup.9 is aryl, heteroaryl, cyclohexane, t-butane,
adamantane, or triazole, and any of R.sup.9 may be substituted with
one to three independently selected of Cl, F, CF.sub.3,
C.sub.1-C.sub.8 alkoxy, NO.sub.2, C.sub.1-C.sub.3 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY,
C(.dbd.O)OY, NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or
C.sub.1-C.sub.14 aryl; or ##STR00159## where R.sup.10 is one of
##STR00160## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, n=1-4, Z and
Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
and heteroaryl substituted with Me, OMe, halide, OH; and
R.sup.5.dbd.H, D-mannose, L-galactose, D-arabinose, L-fucose,
polyols ##STR00161## where X.dbd.CF.sub.3, cyclopropyl or phenyl,
or ##STR00162## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where R.sup.11 is
aryl, heteroaryl, ##STR00163## where Q is H or a physiologically
acceptable salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
35. The method according to claim 33 wherein the compound consists
of the compound of claim 34.
36. The method according to any one of claims 33-35 wherein the
disease is dermatitis.
37. The method according to any one of claims 33-35 wherein the
disease is chronic eczema.
38. The method according to any one of claims 33-35 wherein the
disease is psoriasis.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 12/069,436 filed Feb. 7, 2008, now allowed;
which application claims the benefit under 35 U.S.C. .sctn.119(e)
of U.S. Provisional Patent Application No. 60/900,398 filed Feb. 9,
2007 and U.S. Provisional Patent Application No. 60/932,779 filed
May 31, 2007; which applications are incorporated herein by
reference in their entirety.
BACKGROUND
[0002] 1. Technical Field
[0003] The present invention relates generally to methods for using
oligosaccharide mimics, and more particularly for using
oligosaccharide mimics wherein a cyclohexane derivative is
incorporated.
[0004] 2. Description of the Related Art
[0005] Naturally occurring monosaccharides and oligosaccharides
play a role, or are capable of playing a role, in a variety of
biological processes. In certain cases, non-naturally occurring
monosaccharides and oligosaccharides may serve to replace or even
improve upon their naturally occurring counterparts.
Monosaccharides and particularly oligosaccharides may be difficult,
and thus costly, to produce. Even where the degree of difficulty to
produce is not particularly elevated, the production of
monosaccharides and oligosaccharides may still nevertheless be
costly. This problem is multiplied where a costly monosaccharide or
oligosaccharide needs to be mass produced. While mimics of
monosaccharides and oligosaccharides ("glycomimetics") may improve
upon their biological properties, the cost of producing the mimics
may not be significantly reduced relative to that which they mimic.
The mimics used herein have reduced production cost or reduced
complexity.
[0006] Endothelial dysfunction, including vascular abnormalities,
is associated with a number of diseases. Diabetes is an example of
such a disease. There is a need for improvements in the treatment
of diabetes or symptoms or complications associated therewith.
[0007] Accordingly, there is a need in the art for new methods for
treating diabetes or symptoms or complications associated
therewith. The present invention fulfills these needs and further
provides other related advantages.
BRIEF SUMMARY
[0008] Briefly stated, the invention provides methods for using
oligosaccharide mimic compounds. The mimics are useful, for
example, for the treatment of endothelial dysfunction, including
vascular abnormalities.
[0009] In one embodiment, the present invention provides a method
for treating an endothelial dysfunction comprising administering to
an individual in need thereof in an amount effective to treat the
endothelial dysfunction an oligosaccharide or glycomimetic compound
that contains at least one cyclohexane derivative (i.e., both an
oligosaccharide compound and a glycomimetic compound contain at
least one cyclohexane derivative), wherein the cyclohexane
derivative has the formula:
##STR00001##
wherein, [0010] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0011] R.sup.2.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H;
[0012] the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
[0013] In another embodiment, the present invention provides the
method wherein the compound comprises:
##STR00002##
wherein, [0014] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0015] R.sup.2.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H;
[0016] R.sup.3.dbd.--OH,
##STR00003## [0017] --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
##STR00004##
[0017] where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any of the above ring compounds may be substituted with one to
three independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8
alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY,
NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, or
C.sub.1-C.sub.14 aryl;
[0018] R.sup.4=
##STR00005## [0019] 6' sulfated GlcNAc, 6' carboxylated GlcNAc, 6'
sulfated GalNAc, 6' sulfated galactose, 6' carboxylated
galactose,
##STR00006##
[0019] where Q is H or a physiologically acceptable salt or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.n-aryl or
(CH.sub.2).sub.n-heteroaryl where n is 1-10, and where R.sup.9 is
aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole,
and any of R.sup.9 may be substituted with one to three
independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy,
NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl or C.sub.1-C.sub.14 aryl; or
##STR00007##
[0020] where R.sup.10 is one of
##STR00008## [0021] where Q is H or a physiologically acceptable
salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, n=1-4, Z and
Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
and heteroaryl substituted with Me, OMe, halide, OH; and
[0022] R.sup.5.dbd.H, D-mannose, L-aalactose, D-arabinose,
L-fucose, polyols
##STR00009##
where X.dbd.CF.sub.3, cyclopropyl or phenyl, or
##STR00010## [0023] where Q is H or a physiologically acceptable
salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, [0024] and where
R.sup.11 is aryl, heteroaryl,
[0024] ##STR00011## [0025] where Q is H or a physiologically
acceptable salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
[0026] In another embodiment, the present invention provides the
method wherein the compound consists of:
##STR00012##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined
as above.
[0027] A compound of the methods of the present invention may
include a polyethylene glycol attached thereto. Alternatively,
multimers may be formed whereby the compound is attached to another
of the compound by polyethylene glycol. As used herein, the phrase
"another of the compound" refers to the same or different compound
of the compounds encompassed by the methods of the present
invention; and includes more than one compound in which case the
compound may be the same or different or both. As used herein, the
phrase "attached by polyethylene glycol" refers to the attachment
via one or more polyethylene glycols. Where there is more than one
polyethylene glycol, they may be the same or different. In
embodiments, two or more of the compounds (same or different) are
attached to two or more polyethylene glycols (same or different).
In an embodiment, each polyethylene glycol is attached to multiple
polyethylene glycols, but each compound is attached to only one of
the multiple polyethylene glycols. For example, a specific
embodiment is shown in FIG. 11 of the present disclosure.
[0028] In an embodiment, the compound of a method has the
formula:
##STR00013##
where Q is H or a physiologically acceptable salt, and Me is
methyl. The compound may include a polyethylene glycol attached
thereto. Alternatively, multimers may be formed whereby the
compound is attached to another of the compound by polyethylene
glycol.
[0029] In an embodiment, the compound of a method has the
formula:
##STR00014##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0030] In an embodiment, the compound of a method has the
formula:
##STR00015##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0031] In an embodiment, the compound of a method has the
formula:
##STR00016##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0032] In an embodiment, the compound of a method has the
formula:
##STR00017##
where Q is H or a physiologically acceptable salt, and Me is
methyl. The compound may include a polyethylene glycol attached
thereto. Alternatively, multimers may be formed whereby the
compound is attached to another of the compound by polyethylene
glycol.
[0033] In an embodiment, the compound of a method has the
formula:
##STR00018##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0034] In an embodiment, the compound of a method has the
formula:
##STR00019##
where Me is methyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0035] In an embodiment, the compound of a method has the
formula:
##STR00020##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0036] In an embodiment, the compound of a method has the
formula:
##STR00021##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0037] In an embodiment, the compound of a method has the
formula:
##STR00022##
where Q is H or a physiologically acceptable salt, and Me is
methyl. The compound may include a polyethylene glycol attached
thereto. Alternatively, multimers may be formed whereby the
compound is attached to another of the compound by polyethylene
glycol.
[0038] In an embodiment, the compound of a method has the
formula:
##STR00023##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl. The compound may include a polyethylene glycol
attached thereto. Alternatively, multimers may be formed whereby
the compound is attached to another of the compound by polyethylene
glycol.
[0039] In an embodiment, the compound of a method has the
formula:
##STR00024##
where Q is H or a physiologically acceptable salt, and Me is
methyl. The compound may include a polyethylene glycol attached
thereto. Alternatively, multimers may be formed whereby the
compound is attached to another of the compound by polyethylene
glycol.
[0040] In an embodiment, the compound of a method has the
formula:
##STR00025##
where Me is methyl, Et is ethyl, and Bz in benzoyl. The compound
may include a polyethylene glycol attached thereto. Alternatively,
multimers may be formed whereby the compound is attached to another
of the compound by polyethylene glycol.
[0041] In an embodiment, the compound of a method has the
formula:
##STR00026##
where Me is methyl and Bz in benzoyl. The compound may include a
polyethylene glycol attached thereto. Alternatively, multimers may
be formed whereby the compound is attached to another of the
compound by polyethylene glycol.
[0042] In an embodiment, the compound of a method has the
formula:
##STR00027##
where Me is methyl, Et is ethyl and Bz is benzoyl. The compound may
include a polyethylene glycol attached thereto. Alternatively,
multimers may be formed whereby the compound is attached to another
of the compound by polyethylene glycol.
[0043] In an embodiment, the compound of a method has the
formula:
##STR00028##
where Me is methyl and Bz is benzoyl. The compound may include a
polyethylene glycol attached thereto. Alternatively, multimers may
be formed whereby the compound is attached to another of the
compound by polyethylene glycol.
[0044] In one embodiment, the present invention provides a method
for treating graft vs. host disease comprising administering to an
individual in need thereof in an amount effective to treat graft
vs. host disease an oligosaccharide or glycomimetic compound that
contains at least one cyclohexane derivative, wherein the
cyclohexane derivative has the formula:
##STR00029##
wherein, [0045] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0046] R.sup.2.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H;
[0047] the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
[0048] In one embodiment, the present invention provides the method
immediately above, wherein the compound comprises:
##STR00030##
wherein, [0049] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0050] R.sup.2.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H;
[0051] R.sup.3=--OH,
##STR00031## [0052] --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
##STR00032##
[0052] where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any of the above ring compounds may be substituted with one to
three independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8
alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY,
NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, or
C.sub.1-C.sub.14 aryl;
[0053] R.sup.4=
##STR00033## [0054] 6' sulfated GlcNAc, 6' carboxylated GlcNAc, 6'
sulfated GalNAc, 6' sulfated galactose, 6' carboxylated
galactose,
##STR00034##
[0054] where Q is H or a physiologically acceptable salt or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.n-aryl or
(CH.sub.2).sub.n-heteroaryl where n is 1-10, and where R.sup.9 is
aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole,
and any of R.sup.9 may be substituted with one to three
independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy,
NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl or C.sub.1-C.sub.14 aryl; or
##STR00035##
[0055] where R.sup.10 is one of
##STR00036## [0056] where Q is H or a physiologically acceptable
salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, n=1-4, Z and
Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
and heteroaryl substituted with Me, OMe, halide, OH; and
[0057] R.sup.5.dbd.H, D-mannose, L-galactose, D-arabinose,
L-fucose, polyols
##STR00037##
where X.dbd.CF.sub.3, cyclopropyl or phenyl, or
##STR00038##
where Q is H or a physiologically acceptable salt, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl,
heteroaryl, (CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl
where m is 1-10, and where R.sup.11 is aryl, heteroaryl,
##STR00039## [0058] where Q is H or a physiologically acceptable
salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
[0059] In one embodiment, the present invention provides the method
immediately above wherein the compound consists of:
##STR00040##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined
as above.
[0060] In any of the embodiments pertaining to a method for
treating graft vs. host disease, the compound used therein may be
any one of the individual compounds disclosed separately above.
Similarly, any description herein related to polyethylene glycol is
also applicable to these embodiments.
[0061] In one embodiment, the present invention provides a method
for treating cutaneous T-cell lymphoma comprising administering to
an individual in need thereof in an amount effective to treat
cutaneous T-cell lymphoma an oligosaccharide or glycomimetic
compound that contains at least one cyclohexane derivative, wherein
the cyclohexane derivative has the formula:
##STR00041##
wherein, [0062] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH;
[0063] R.sup.2.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, OH, or NHX where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; --C(.dbd.O)OX where X is C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or
heteroaryl either of which may be substituted with one or more of
Me, OMe, halide, or OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where
n=0-30, C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; with the proviso that R.sup.1 and R.sup.2 are not
both H;
[0064] the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
[0065] In one embodiment, the present invention provides the method
immediately above, wherein the compound comprises:
##STR00042##
wherein, [0066] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0067] R.sup.2.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H;
[0068] R.sup.3=--OH,
##STR00043## [0069] --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
##STR00044##
[0069] where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any of the above ring compounds may be substituted with one to
three independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8
alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY,
NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, or
C.sub.1-C.sub.14 aryl;
[0070] R.sup.4=
##STR00045## [0071] 6' sulfated GlcNAc, 6' carboxylated GlcNAc, 6'
sulfated GalNAc, 6' sulfated galactose, 6' carboxylated
galactose,
##STR00046##
[0071] where Q is H or a physiologically acceptable salt or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.n-aryl or
(CH.sub.2).sub.n-heteroaryl where n is 1-10, and where R.sup.9 is
aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole,
and any of R.sup.9 may be substituted with one to three
independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy,
NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl or C.sub.1-C.sub.14 aryl; or
##STR00047##
[0072] where R.sup.10 is one of
##STR00048## [0073] where Q is H or a physiologically acceptable
salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, n=1-4, Z and
Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
and heteroaryl substituted with Me, OMe, halide, OH; and
[0074] R.sup.5.dbd.H, D-mannose, L-aalactose, D-arabinose,
L-fucose, polyols
##STR00049## [0075] where X.dbd.CF.sub.3, cyclopropyl or phenyl,
or
##STR00050##
[0075] where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where R.sup.11 is
aryl, heteroaryl,
##STR00051## [0076] where Q is H or a physiologically acceptable
salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
[0077] In one embodiment, the present invention provides the method
immediately above wherein the compound consists of:
##STR00052##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined
as above.
[0078] In any of the embodiments pertaining to a method for
treating cutaneous T-cell lymphoma, the compound used therein may
be any one of the individual compounds disclosed separately above.
Similarly, any description herein related to polyethylene glycol is
also applicable to these embodiments.
[0079] In one embodiment, the present invention provides a method
for treating disease involving inflammatory cells in the skin
comprising administering to an individual in need thereof in an
amount effective to treat disease involving inflammatory cells in
the skin an oligosaccharide or glycomimetic compound that contains
at least one cyclohexane derivative, wherein the cyclohexane
derivative has the formula:
##STR00053##
wherein, [0080] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0081] R.sup.2.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H;
[0082] the cyclohexane derivative is at least attached to the
oligosaccharide or glycomimetic compound at an OH, R.sup.1 or
R.sup.2.
[0083] In one embodiment, the present invention provides the method
immediately above, wherein the compound comprises:
##STR00054##
wherein, [0084] R.sup.1.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, OH, or NHX where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; C(.dbd.O)OX, alkanyl substituted with
C(.dbd.O)OX, C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX,
where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0085] R.sup.2.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H;
[0086] R.sup.3=--OH,
##STR00055## [0087] --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
##STR00056##
[0087] where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any of the above ring compounds may be substituted with one to
three independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8
alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY,
NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, or
C.sub.1-C.sub.14 aryl;
[0088] R.sup.4=
##STR00057## [0089] 6' sulfated GlcNAc, 6' carboxylated GlcNAc, 6'
sulfated GalNAc, 6' sulfated galactose, 6' carboxylated
galactose,
[0089] ##STR00058## [0090] where Q is H or a physiologically
acceptable salt or C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl,
(CH.sub.2).sub.n-aryl or (CH.sub.2).sub.n-heteroaryl where n is
1-10, and where R.sup.9 is aryl, heteroaryl, cyclohexane, t-butane,
adamantane, or triazole, and any of R.sup.9 may be substituted with
one to three independently selected of Cl, F, CF.sub.3,
C.sub.1-C.sub.8 alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY,
C(.dbd.O)OY, NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or
C.sub.1-C.sub.14 aryl; or
[0090] ##STR00059## [0091] where R.sup.10 is one of
[0091] ##STR00060## ##STR00061## [0092] where Q is H or a
physiologically acceptable salt, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl,
(CH.sub.2).sub.m-aryl or (CH.sub.2).sub.m-heteroaryl where m is
1-10, n=1-4, Z and Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH;
and
[0093] R.sup.5.dbd.H, D-mannose, L-galactose, D-arabinose,
L-fucose, polyols
##STR00062## [0094] where X.dbd.CF.sub.3, cyclopropyl or phenyl,
or
[0094] ##STR00063## [0095] where Q is H or a physiologically
acceptable salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, [0096] and where
R.sup.11 is aryl, heteroaryl,
[0096] ##STR00064## [0097] where Q is H or a physiologically
acceptable salt, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
[0098] In one embodiment, the present invention provides the method
immediately above wherein the compound consists of:
##STR00065##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined
as above.
[0099] In any of the embodiments pertaining to a method for
treating disease involving inflammatory cells in the skin, the
compound used therein may be any one of the individual compounds
disclosed separately above. Similarly, any description herein
related to polyethylene glycol is also applicable to these
embodiments.
[0100] These and other aspects of the present invention will become
apparent upon reference to the following detailed description and
attached drawings. All references disclosed herein are hereby
incorporated by reference in their entirety as if each was
incorporated individually.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0101] FIG. 1 is a diagram illustrating the synthesis of GlcNAc
mimics from tetrahydrophthalic anhydride.
[0102] FIG. 2 is a diagram illustrating the synthesis of GlcNAc
mimics from cyclohexenon.
[0103] FIG. 3 is a diagram illustrating the synthesis of
mimics.
[0104] FIG. 4 is a diagram illustrating the synthesis of
mimics.
[0105] FIG. 5 is a diagram illustrating the synthesis of
mimics.
[0106] FIG. 6 is a diagram illustrating the synthesis of
mimics.
[0107] FIG. 7 is a diagram illustrating the synthesis of
mimics.
[0108] FIG. 8 is a diagram illustrating the synthesis of
mimics.
[0109] FIG. 9 is a diagram illustrating the synthesis of
mimics.
[0110] FIG. 10 is a diagram illustrating the synthesis of a
pegylated mimic.
[0111] FIG. 11 is a diagram illustrating the synthesis of a
pegylated tetramer of a mimic.
[0112] FIG. 12 is a diagram illustrating the synthesis of
mimics.
[0113] FIG. 13 is a diagram illustrating the synthesis of
mimics.
[0114] FIG. 14 is a diagram of a timeline for the experiments for
observing the effects of a test compound (an oligosaccharide mimic)
on microvascular flow in sickle cell mice as determined by
intravital microscopy.
[0115] FIG. 15 is a graphical representation of the effects of a
test compound (FIG. 14) on cell adhesion to the endothelium during
an induced vaso-occlusive crisis in sickle cell mice as determined
by intravital microscopy.
[0116] FIG. 16 is a graphical representation of the effects of a
test compound (FIG. 14) on the number of SS red blood cells
adherent to leukocytes during an induced vaso-occlusive crisis in a
sickle cell mouse as determined by intravital microscopy.
[0117] FIG. 17 is a graphical representation of the effects of a
test compound (FIG. 14) on the average survival of sickle cell mice
after induction of a vaso-occlusive crisis.
[0118] FIG. 18 is a graphical representation of induction of
neutrophil adhesion under flow by glycated human serum albumin
(Gly-HSA) treatment of human endothelial cells.
[0119] FIG. 19 is a graphical representation of induction of
neutrophil adhesion under flow by glycated hemaglobin (Gly-Hb)
treatment of human endothelial cells.
[0120] FIG. 20 is a graphical representation of the blockade by
test compound (at three concentrations) of glycated albumin-induced
neutrophil adhesion under flow.
[0121] FIG. 21 is a graphical representation of leukocyte rolling
in diabetic mice, with and without test compound (FIG. 14), as
measured by intravital microscopy.
DETAILED DESCRIPTION
[0122] As noted above, the present invention provides methods for
using oligosaccharide mimics. Such mimics have a variety of uses in
vitro and in vivo.
[0123] An oligosaccharide mimic (compound) may be prepared by
incorporating one or more cyclohexane derivatives into an
oligosaccharide or glycomimetic compound. An oligosaccharide refers
to two or more monosaccharides covalently joined. Oligosaccharides
are polymers containing monosaccharide units, typically with 2 to
about 100 monosaccharides and any integer in-between. Each
monosaccharide of an oligosaccharide is independently selected;
although two or more monosaccharides may be identical.
[0124] The cyclohexane derivative of an oligosaccharide or
glycomimetic compound of the methods of the present invention has
the formula:
##STR00066##
R.sup.1 may be H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, OH, or NHX where X.dbd.H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; C(.dbd.O)OX, alkanyl substituted with C(.dbd.O)OX,
C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX, where
X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH. R.sup.2 may be H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H. The cyclohexane
derivative is attached to the oligosaccharide or glycomimetic
compound at least at one of the OH, the R.sup.1 or the R.sup.2. In
embodiments, attachment is at least at one of the OH or the
R.sup.2. Other options for attachment include at both of the OH,
e.g., one monosaccharide or monosaccharide mimic attached at one of
the OH and another monosaccharide or monosaccharide mimic attached
at the other OH.
[0125] As used herein, a "C.sub.1-C.sub.8 alkanyl" refers to an
alkane substituent with one to eight carbon atoms and may be
straight chain, branched or cyclic (cycloalkanyl). Examples are
methyl, ethyl, propyl, isopropyl, butyl and t-butyl. A "halogenated
C.sub.1-C.sub.8 alkanyl" refers to a "C.sub.1-C.sub.8 alkanyl"
possessing at least one halogen. Where there is more than one
halogen present, the halogens present may be the same or different
or both (if at least three present). A "C.sub.1-C.sub.8 alkenyl"
refers to an alkene substituent with one to eight carbon atoms, at
least one carbon-carbon double bond, and may be straight chain,
branched or cyclic (cycloalkenyl). Examples are similar to
"C.sub.1-C.sub.8 alkanyl" examples except possessing at least one
carbon-carbon double bond. A "C.sub.1-C.sub.8 alkynyl" refers to an
alkyne substituent with one to eight carbon atoms, at least one
carbon-carbon triple bond, and may be straight chain, branched or
cyclic (cycloalkynyl). Examples are similar to "C.sub.1-C.sub.8
alkanyl" examples except possessing at least one carbon-carbon
triple bond. An "alkoxy" refers to an oxygen substituent possessing
a "C.sub.1-C.sub.8 alkanyl," "C.sub.1-C.sub.8 alkenyl" or
"C.sub.1-C.sub.8 alkynyl." This is --O-alkyl; for example methoxy,
ethoxy, n-propoxy, i-propoxy, n-butoxy and the like; and alkenyl or
alkynyl variations thereof (except for methoxy). It further refers
to the group O-alkyl-W-alkyl where W is O or N; for example
--O--(CH.sub.2).sub.n--W--(CH.sub.2).sub.m where n and m are
independently 1-10. An "aryl" refers to an aromatic substituent
with one to fourteen carbon atoms in one or multiple rings which
may be separated by a bond or fused. A "heteroaryl" is similar to
an "aryl" except the aromatic substituent possesses at least one
heteroatom (such as N, O or S) in place of a ring carbon. Examples
of aryls and heteroaryls include phenyl, naphthyl, pyridinyl,
pyrimidinyl, triazolo, furanyl, oxazolyl, thiophenyl, quinolinyl
and diphenyl. As used herein, the term "independently selected"
refers to the selection of identical or different substituents.
"Me" and "Et" represent methyl and ethyl, respectively. "Bz"
represents benzoyl. "Ar" represents aryl. Examples of
physiologically acceptable salts include Na, K, Li, Mg and Ca.
Monosaccharide substituents recited herein (e.g., D-mannose,
L-galactose, D-arabinose and L-fucose) may be in the furanose,
pyranose or open form.
[0126] A linker arm may be desirable for attachment, for example,
to a monosaccharide, a monosaccharide mimic or something else. A
linker may include a spacer group, such as --(CH.sub.2).sub.n-- or
--O(CH.sub.2).sub.n-- where n is generally about 1-20 (all number
ranges disclosed herein include any whole integer range therein).
An example of a linker is --NH.sub.2, e.g., --CH.sub.2--NH.sub.2
when it includes a short spacer group.
[0127] Embodiments of linkers include the following:
##STR00067##
Other linkers with or without a spacer group (e.g.,
CONH(CH.sub.2).sub.2NH.sub.2, COOMe, or polyethylene glycol or
derivative) will be familiar to those in the art or in possession
of the present disclosure.
[0128] Alternatively, or in combination with a linker arm, a
cyclohexane derivative may be attached at one or both OH.
[0129] In another embodiment is provided the use in a method of a
compound comprising:
##STR00068## [0130] R.sup.1 of the formula may be H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, OH, or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH;
C(.dbd.O)OX, alkanyl substituted with C(.dbd.O)OX, C(.dbd.O)NHX,
alkanyl substituted with C(.dbd.O)NHX, where X.dbd.C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; [0131] R.sup.2 of the formula may be H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, OH, or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH;
--C(.dbd.O)OX where X is C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, or
OH; --C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30,
C(.dbd.O)NHX or CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; O(.dbd.O)X,
OX, NHX, NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H; [0132] R.sup.3 of
the formula may be --OH,
[0132] ##STR00069## --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
##STR00070## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any of the above ring compounds may be substituted with one to
three independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8
alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY,
NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, or
C.sub.1-C.sub.14 aryl;
##STR00071## [0133] R.sup.4 of the formula may be 6' sulfated
GlcNAc, 6' carboxylated GlcNAc, 6' sulfated GalNAc, 6' sulfated
galactose, 6' carboxylated galactose,
[0133] ##STR00072## where Q is H or a physiologically acceptable
salt or C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, aryl, heteroaryl, (CH.sub.2).sub.n-aryl or
(CH.sub.2).sub.n-heteroaryl where n is 1-10, and where R.sup.9 is
aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole,
and any of R.sup.9 may be substituted with one to three
independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy,
NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl or C.sub.1-C.sub.14 aryl; or
##STR00073## where R.sup.10 is one of
##STR00074## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, n=1-4, Z and
Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
and heteroaryl substituted with Me, OMe, halide, OH; and [0134]
R.sup.5 of the formula may be H, D-mannose, L-galactose,
D-arabinose, polyols, L-fucose,
[0134] ##STR00075## where X.dbd.CF.sub.3, cyclopropyl or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, or
##STR00076## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where R.sup.11 is
aryl, heteroaryl,
##STR00077## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
[0135] In another embodiment is provided the use in a method of a
compound consisting of:
##STR00078##
[0136] R.sup.1 is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, OH, or NHX where X.dbd.H,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl
either of which may be substituted with one or more of Me, OMe,
halide, or OH; C(.dbd.O)OX, alkanyl substituted with C(.dbd.O)OX,
C(.dbd.O)NHX, alkanyl substituted with C(.dbd.O)NHX, where
X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX, NH(.dbd.O)X, where
X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
or heteroaryl either of which may be substituted with one or more
of Me, OMe, halide, or OH; [0137] R.sup.2 is H, C.sub.1-C.sub.8
alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
halogenated C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of
which may be substituted with one or more of Me, OMe, halide, OH,
or NHX where X.dbd.H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; --C(.dbd.O)OX where X is
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH;
--C(.dbd.O)NH(CH.sub.2).sub.nNH.sub.2 where n=0-30, C(.dbd.O)NHX or
CX.sub.2OH, where X.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8
alkanyl, aryl or heteroaryl either of which may be substituted with
one or more of Me, OMe, halide, or OH; O(.dbd.O)X, OX, NHX,
NH(.dbd.O)X, where X.dbd.H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, halogenated
C.sub.1-C.sub.8 alkanyl, aryl or heteroaryl either of which may be
substituted with one or more of Me, OMe, halide, or OH; with the
proviso that R.sup.1 and R.sup.2 are not both H; [0138] R.sup.3 is
--OH,
[0138] ##STR00079## --O--C(.dbd.O)--X, --NH.sub.2,
--NH--C(.dbd.O)--NHX, or --NH--C(.dbd.O)--X where n=0-2 and X is
independently selected from C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl,
##STR00080## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any of the above ring compounds may be substituted with one to
three independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8
alkoxy, NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.14 aryl, or OY, C(.dbd.O)OY,
NY.sub.2 or C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, or
C.sub.1-C.sub.14 aryl; [0139] R.sup.4 is
[0139] ##STR00081## 6' sulfated GlcNAc, 6' carboxylated GlcNAc, 6'
sulfated GalNAc, 6' sulfated galactose, 6' carboxylated
galactose,
##STR00082## where Q is H or a physiologically acceptable salt or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.n-aryl or
(CH.sub.2).sub.n-heteroaryl where n is 1-10, and where R.sup.9 is
aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole,
and any of R.sup.9 may be substituted with one to three
independently selected of Cl, F, CF.sub.3, C.sub.1-C.sub.8 alkoxy,
NO.sub.2, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl or OY, C(.dbd.O)OY, NY.sub.2 or
C(.dbd.O)NHY where Y is H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkynyl or C.sub.1-C.sub.14 aryl; or
##STR00083## where R.sup.10 is one of
##STR00084## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, n=1-4, Z and
Y.dbd.C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkynyl, halogenated C.sub.1-C.sub.8 alkanyl, aryl
and heteroaryl substituted with Me, OMe, halide, OH; and [0140]
R.sup.5 is H, D-mannose, L-galactose, D-arabinose, L-fucose,
polyols,
[0140] ##STR00085## where X.dbd.CF.sub.3, cyclopropyl or
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, or
##STR00086## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where R.sup.11 is
aryl, heteroaryl,
##STR00087## where Q is H or a physiologically acceptable salt,
C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkynyl, aryl, heteroaryl, (CH.sub.2).sub.m-aryl or
(CH.sub.2).sub.m-heteroaryl where m is 1-10, and where n=0-10, and
any one of the above ring compounds may be substituted with one to
three independently selected of Cl, F, C.sub.1-C.sub.8 alkanyl,
C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl or OY where Y is
H, C.sub.1-C.sub.8 alkanyl, C.sub.1-C.sub.8 alkenyl or
C.sub.1-C.sub.8 alkynyl.
[0141] In another embodiment is provided the use in a method of a
compound having the formula:
##STR00088##
where Q is H or a physiologically acceptable salt, and Me is
methyl.
[0142] In another embodiment is provided the use in a method of a
compound having the formula:
##STR00089##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl.
[0143] In another embodiment is provided the use in a method of a
compound having the formula:
##STR00090##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl.
[0144] In another embodiment is provided the use in a method of a
compound having the formula:
##STR00091##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl.
[0145] In another embodiment is provided the use in a method of a
compound having the formula:
##STR00092##
where Q is H or a physiologically acceptable salt, and Me is
methyl.
[0146] In another embodiment is provided the use in a method of a
compound having the formula:
##STR00093##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl.
[0147] In another embodiment is provided the use in a method of a
compound having the formula:
##STR00094##
where Me is methyl.
[0148] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00095##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl.
[0149] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00096##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl.
[0150] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00097##
where Q is H or a physiologically acceptable salt, and Me is
methyl.
[0151] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00098##
where Q is H or a physiologically acceptable salt, Me is methyl and
Bz is benzoyl.
[0152] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00099##
where Q is H or a physiologically acceptable salt, and Me is
methyl.
[0153] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00100##
where Me is methyl, Et is ethyl, and Bz in benzoyl. The compound
may include a polyethylene glycol attached thereto. Alternatively,
multimers may be formed whereby the compound is attached to another
of the compound by polyethylene glycol.
[0154] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00101##
where Me is methyl and Bz in benzoyl. The compound may include a
polyethylene glycol attached thereto. Alternatively, multimers may
be formed whereby the compound is attached to another of the
compound by polyethylene glycol.
[0155] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00102##
where Me is methyl, Et is ethyl and Bz is benzoyl. The compound may
include a polyethylene glycol attached thereto. Alternatively,
multimers may be formed whereby the compound is attached to another
of the compound by polyethylene glycol.
[0156] In an embodiment, the present invention provides the use in
a method of a compound having the formula:
##STR00103##
where Me is methyl and Bz is benzoyl. The compound may include a
polyethylene glycol attached thereto. Alternatively, multimers may
be formed whereby the compound is attached to another of the
compound by polyethylene glycol.
[0157] For the compounds described herein, a free acid substituent,
e.g., CO.sub.2H and (O.dbd.)S(.dbd.O)OH, encompasses a sodium salt
of the acid, e.g., COONa and (O.dbd.)S(.dbd.O)ONa, and vice versa.
Furthermore, a sodium salt of the acid is merely representative and
any physiologically acceptable acid salt (e.g., Li, K, Mg and Ca)
is encompassed. In addition, for the compounds described herein, a
free acid substituent (or salt thereof) may be modified as an ester
(e.g., alkanyl ester) or as an amide or amide-like (e.g.,
CONHOH).
[0158] For the compounds described herein (both generically and
specifically), a polyethylene glycol (PEG), including derivatives
thereof, may be attached to a compound. Alternatively, multimers of
the same compound or different compounds of the compounds described
herein (i.e., two or more compounds joined to one another) may be
formed using PEG. Examples of particular compounds amenable to the
attachment of a PEG or to the formation of a multimer including
PEG, are disclosed above as embodiments of the present invention.
Procedures for preparing a pegylated compound or pegylated
multimers will be familiar to those in the art or in possession of
the present disclosure. Examples are depicted in FIG. 10 (a
pegylated compound) and FIG. 11 (a pegylated tetramer).
[0159] An oligosaccharide or glycomimetic compound as described
herein is administered to an individual in need thereof to treat an
endothelial dysfunction (including a condition or symptom
associated therewith, e.g., pain). Endothelial dysfunction includes
vascular abnormalities. Vascular abnormalities are associated with
diseases such as diabetes, sickle cell disease (e.g., sickle cell
anemia), and atherosclerosis. An oligosaccharide or glycomimetic
compound as described herein may be administered in combination
(e.g., simultaneous, sequential or otherwise) with another therapy.
For example, aspirin therapy is used for atherosclerosis. An
oligosaccharide or glycomimetic compound as described herein may be
administered in combination with aspirin therapy. Aspirin therapy
may utilize aspirin or an aspirin substitute which is useful for
atherosclerosis.
[0160] An oligosaccharide or glycomimetic compound as described
herein is also useful to treat (e.g., via an orally available
formulation) graft vs. host disease (GVHD) that commonly arises in
patients post stem cell transplantation. Additional uses include
for cutaneous T-cell lymphoma, such as mycosis fungoides and Sezary
syndrome. An oligosaccharide or glycomimetic compound as described
herein can also treat other diseases involving inflammatory cells
in the skin, such as dermatitis, chronic eczema and psoriasis.
[0161] An oligosaccharide or glycomimetic compound as described
herein of the present methods may be administered in a manner
appropriate to the disease to be treated (including prevented and
delay of onset). Appropriate dosages and a suitable duration and
frequency of administration may be determined by such factors as
the condition of the patient, the type and severity of the
patient's disease and the method of administration. In general, an
appropriate dosage and treatment regimen provides the
oligosaccharide or glycomimetic compound as described herein in an
amount sufficient to provide therapeutic and/or prophylactic
benefit. Within particularly preferred embodiments of the
invention, an oligosaccharide or glycomimetic compound as described
herein may be administered at a dosage ranging from 0.001 to 1000
mg/kg body weight (more typically 0.01 to 1000 mg/kg), on a regimen
of single or multiple daily doses. Appropriate dosages may
generally be determined using experimental models and/or clinical
trials. In general, the use of the minimum dosage that is
sufficient to provide effective therapy is preferred. Patients may
generally be monitored for therapeutic effectiveness using assays
suitable for the condition being treated or prevented, which will
be familiar to those of ordinary skill in the art.
[0162] As used herein, treating (or treatment) by administering an
effective amount of at least one oligosaccharide or glycomimetic
compound as described herein refers to any indicia of success in
the treatment or amelioration of a disease, disorder, dysfunction
or abnormality, or one or more symptoms or conditions thereof.
Indicia of success include any objective or subjective parameter,
such as abatement, remission, cure, diminishing of symptoms (such
as pain) or conditions, making the symptom or condition more
tolerable to the individual, slowing in the rate of degeneration or
decline, improving an individual's physical or mental well-being,
slowing or inhibiting progression, delaying the onset or prolonging
the survival time. The method may further comprise inclusion of one
or more other types of therapeutic agents. Alternatively, the
method may be used in conjunction with one or more other therapies.
Individuals treated include human and non-human animals, such as
pets, animals for racing, animals for show and exotic animals.
Typically, an animal is a warm-blooded animal.
[0163] The following Examples are offered by way of illustration
and not by way of limitation.
EXAMPLES
Example 1
Synthesis of GlcNac Mimic from tetrahydrophthalic Anhydride (FIG.
1)
Synthesis of Intermediate I
[0164] Amberlyste 15 (50.0 g) was placed in a flask and dried in
high vacuo for 1 h. Methanol (1 l) was added, followed by
cis-1,2,3,6-tetrahydrophthalic anhydride (50.0 g, 328 mmol) and
trimethylorthoformate (100 ml, 914 mmol). The reaction mixture was
then vigorously stirred. After 5 days, additional
trimethylorthoformate (50 ml, 457 mmol) was added. The reaction was
stopped after 9 days (TLC-control: petroleum ether/Et.sub.20, 1:2),
filtered over celite and washed with methanol. The solvent was
removed in vacuo (20 mbar). The brown residue was transferred with
CH.sub.2Cl.sub.2 (150 ml) into a separation funnel and washed with
satd. NaHCO.sub.3 solution and brine (each 150 ml). The aqueous
layers were extracted 3 times with CH.sub.2Cl.sub.2 (3.times.150
ml). The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo (20 mbar) to afford diester I as
a brownish oil (57.5 g, 88%).
Synthesis of Intermediate II
[0165] To a stirred suspension of diester I (2.00 g, 10.1 mmol) in
pH 7.00 phosphate buffer solution (103 ml, 0.07 M), PLE (8.00 mg,
216 units) was added. The pH was kept at 7 by adding continuously
NaOH solution (1.0 M) via syringe pump. The reaction was stirred at
20.degree. C. until one equivalent of NaOH (10 ml) was used (56.5
h, TLC-control: petroleum ether/Et.sub.20, 1:2). The reaction
mixture was transferred into a separation funnel with ethyl acetate
(100 ml). The layers were separated and the organic layer was
extracted twice with pH 7.00 phosphate buffer solution (2.times.60
ml). The combined aqueous layers were acidified to pH 2 with 1 M
HCl solution and extracted four times with ethyl acetate
(4.times.150 ml). To separate the layers NaCl was added. The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo to afford the monoester II as a yellowish
oil (1.67 g, 90%). 96.0% ee. (GC), 96.4% ee. (rot.),
[.alpha.].sub.D.sup.21+15.23.degree. (c=0.195, EtOH), (Lit.
+15.8.degree. (c=0.2, EtOH), [Angew. Chem. Int. Ed. Engl., 1984,
23, 142]).
Synthesis of Intermediate III
[0166] A solution of monoester II (0.992 g, 5.38 mmol) in dry
CH.sub.2Cl.sub.2 (18 ml) was treated with (COCl).sub.2 (0.7 ml,
8.15 mmol) and DMF (14 .mu.l), stirred for 3 h at r.t. and
evaporated (rotavapor purged with argon). A solution of the residue
in dry THF (20 ml) was added dropwise over a period of 20 minutes
to a boiling suspension of 2-mercaptopyridine-1-oxide sodium salt
(974.8 mg, 6.49 mmol), t-BuSH (3.1 ml, 27.5 mmol), and 4-DMAP (26.3
mg, 0.216 mmol) in dry THF (50 ml). The solution was stirred at
reflux for 3 h (TLC-control: petroleum ether/Et.sub.2O, 10:1). The
reaction mixture was then cooled down to r.t. (room temperature)
and transferred into a separation funnel with ethyl acetate (50 ml)
and washed with water (100 ml). The aqueous layer was extracted
twice with ethyl acetate (2.times.100 ml). The combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
in vacuo (200 mbar). The crude product was purified by column
chromatography (petroleum ether/Et.sub.2O, 30:1 to 15:1) to afford
methylester III as a yellowish oil (584.9 mg, 83%).
[.alpha.]D.sup.21+78.23.degree. (c=1.010, CHCl.sub.3).
Synthesis of Intermediate IV
[0167] To a stirred suspension of methylester III (5.19 g, 37.0
mmol) in pH 7.00 phosphate buffer solution (520 ml, 0.07 M), PLE
(51.2 mg, 1382 units) was added. The pH was kept at 7 by adding
NaOH solution (1.0 M) via syringe pump. The reaction was stirred at
r.t. until one equivalent of NaOH (37 ml) was used (11 h,
TLC-control: petroleum ether/Et.sub.20, 1:1). The reaction mixture
was transferred into a separation funnel and washed twice with
ethyl acetate (2.times.300 ml). The layers were separated and the
organic layers were extracted twice with pH 7.00 phosphate buffer
solution (2.times.300 ml). The combined aqueous layers were
acidified to pH 2 with aqueous HCl (30 ml, 4 M) and extracted three
times with ethyl acetate (3.times.400 ml). The combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
in vacuo (100 mbar). The crude product was filtered through a short
plug of silica affording acid IV as a pale yellowish oil (3.92 g,
84%). 96.3% ee. (GC), 94.3% ee. (rot.),
[.alpha.].sub.D.sup.21+89.12.degree. (c=6.730, MeOH), (Lit.
+94.5.degree. (c=7, MeOH), [Acta Chem. Scand., 1970, 24,
2693]).
Synthesis of Intermediate V
[0168] Acid IV (8.30 g, 65.7 mmol) was placed in a flask purged
with argon and suspended in water (180 ml). The reaction mixture
was cooled down to 0.degree. C. and NaHCO.sub.3 (16.6 g, 197 mmol)
was added, followed by a solution of KI (65.4 g, 394 mmol) and
iodine (17.5 g, 68.9 mmol) in water (150 ml). The reaction was
stirred at r.t. for 24 h and then extracted three times with
CH.sub.2Cl.sub.2 (3.times.60 ml). The combined organic layers were
washed with a solution of Na.sub.2S.sub.2O.sub.3 (50 g) in water
(250 ml). The aqueous layer was extracted twice with
CH.sub.2Cl.sub.2 (2.times.60 ml). The combined organic layers were
protected from light, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo (20 mbar) and quickly in high vacuo to afford
iodolactone V as an off-white solid (15.79 g, 95%).
[.alpha.].sub.D.sup.21+35.96.degree. (c=0.565, CHCl.sub.3).
Synthesis of Intermediate VI
[0169] Iodolactone V (15.73 g, 62.2 mmol) was dissolved in dry THF
(340 ml). Then DBU (14 ml, 93.3 mmol) was added and the mixture was
refluxed for 20 h (TLC-control: petroleum ether/Et.sub.20, 1:1).
The reaction mixture was cooled down to r.t., transferred with
Et.sub.2O (200 ml) into a separation funnel and extracted with
aqueous HCl (400 ml, 0.5 M) and brine (400 ml). The aqueous layers
were extracted three times with Et.sub.2O (3.times.200 ml). The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo (350 mbar). The crude product was
purified by column chromatography (petroleum
ether/CH.sub.2Cl.sub.2/Et.sub.2O, 20:5:1 to 8:5:1) to afford
lactone VI as a yellowish oil (7.28 g, 94%).
[.alpha.].sub.D.sup.21+187.31.degree. (c=1.080, CHCl.sub.3).
Synthesis of Intermediate VII
[0170] NaHCO.sub.3 (4.36 g, 51.8 mmol) was dried in high vacuum for
2 h. Then, freshly distilled methanol (268 ml) was added followed
by lactone VI (6.38 g, 51.4 mmol). The reaction mixture was then
stirred under argon for 12 h (TLC-control: petroleum
ether/Et.sub.20, 1:1). The solvent was evaporated and the residue
transferred into a separation funnel with CH.sub.2Cl.sub.2 (60 ml)
and extracted with water (60 ml) and brine (60 ml). The aqueous
layers were extracted twice with CH.sub.2Cl.sub.2 (2.times.60 ml).
The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo (50 mbar) to obtain the alcohol
as a yellowish oil (7.77 g, 96%). To a solution of the alcohol in
dry CH.sub.2Cl.sub.2 (150 ml), tert-butyldimethylsilyl chloride
(14.93 g, 99 mmol) was added in small portions, followed by DBU
(18.4 ml, 123.4 mmol). The reaction was stirred at r.t for 12 h
(TLC-control: petroleum ether/Et.sub.2O, 20:1) and then quenched
with methanol (20 ml). The reaction mixture was transferred into a
separation funnel with CH.sub.2Cl.sub.2 (100 ml), washed with satd.
NaHCO.sub.3 solution (100 ml) and brine (100 ml). The aqueous
layers were extracted twice with CH.sub.2Cl.sub.2 (2.times.100 ml).
The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and evaporated (200 mbar). The crude product was purified
by column chromatography (petroleum ether/Et.sub.2O, 40:1 to 20:1)
to afford silylether VII as a colorless oil (13.96 g, quantitative
yield). [.alpha.].sub.D.sup.21+1.97.degree. (c=1.045,
CHCl.sub.3).
Synthesis of Intermediate VIII
[0171] A solution of silylether VII (1.21 g, 4.47 mmol) in
CH.sub.2Cl.sub.2 (36 ml) was cooled to 10.degree. C., then m-CPBA
(1.92 g, 11.1 mmol) was added in one portion. The reaction mixture
was stirred at 10.degree. C. for 15 h. Over a period of 2 hours the
temperature was raised to r.t and the reaction stopped
(TLC-control: petroleum ether/Et.sub.2O, 5:1). The mixture was
diluted with CH.sub.2Cl.sub.2 (150 ml) and transferred into a
separation funnel. The excess of m-CPBA was destroyed by washing
twice with satd. Na.sub.2S.sub.2O.sub.3 solution (2.times.150 ml).
The organic layer was successively washed with satd. NaHCO.sub.3
solution (150 ml) and brine (150 ml). The aqueous layers were
extracted twice with CH.sub.2Cl.sub.2 (2.times.100 ml). The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. The crude product was purified by column
chromatography (petroleum ether/Et.sub.2O, 12:1 to 10:1) to obtain
epoxide VIII as yellowish oil (1.001 g, 78%).
[.alpha.].sub.D.sup.21-25.60 (c=0.985, CHCl.sub.3).
Synthesis of Intermediate IX
[0172] CuCN (635.4 mg, 7.09 mmol) was dried in high vacuo at
150.degree. C. for 30 minutes, suspended in dry THF (10 ml) and
cooled down to -78.degree. C. MeLi (1.6 M in Et.sub.2O, 8.90 ml,
14.2 mmol) was slowly added via syringe and the temperature was
raised over a period of 30 minutes to -10.degree. C. The mixture
was again cooled down to -78.degree. C. followed by the addition of
freshly distilled BF.sub.3 etherate (360 .mu.l) in THF (2 ml).
After stirring for 20 minutes, epoxide VIII (408.0 mg, 1.42 mmol)
in THF (10 ml) was added. The reaction was stopped after 5 h
stirring at -78.degree. C. (TLC-control: petroleum ether/Et.sub.2O,
3:1). The excess of MeLi was quenched with a mixture of methanol (4
ml) and triethylamine (4 ml). The mixture was transferred with
Et.sub.2O (100 ml) into a separation funnel and extracted with 25%
aq. NH.sub.3/satd. NH.sub.4Cl (1:9) solution. The organic layer was
then successively washed with brine (60 ml), 5% acetic acid (60
ml), satd. NaHCO.sub.3 solution (60 ml) and brine (60 ml). The
aqueous layers were extracted twice with Et.sub.2O (2.times.100
ml). The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo (20 mbar). The crude product was
purified by column chromatography (petroleum ether/Et.sub.2O, 10:1
to 8:1) to afford GlcNAc-mimic IX as a reddish oil (337.0 mg, 78%).
[.alpha.].sub.D.sup.21-28.34.degree. (c=1.020, CHCl.sub.3).
Synthesis of Intermediate X
[0173] After a mixture of IX (347.5 mg, 1.15 mmol), ethyl
2,3,4-tri-O-benzyl-L-fucothiopyranoside (1.111 g, 2.32 mmol),
(Bu).sub.4NBr (1.122 g, 3.48 mmol),
2,6-di-tert-butyl-4-methylpyridine (713.3 mg, 3.47 mmol), and
powdered 4 .ANG. molecular sieves (3 g) in CH.sub.2Cl.sub.2 (12 ml)
and DMF (3 ml) was stirred at r.t. under Ar for 4 h, CuBr.sub.2
(775.9 mg, 3.47 mmol) was added and the reaction mixture was
stirred at r.t. for 20 h (TLC-control: toluene/petroleum
ether/EtOAc, 3:3:1). The reaction mixture was filtered over Celite
and the filtrate was diluted with CH.sub.2Cl.sub.2 (20 ml). The
organic layer was washed with satd. NaHCO.sub.3 solution and brine
(each 40 ml) and the aqueous layers were extracted three times with
CH.sub.2Cl.sub.2 (3.times.40 ml). The combined organic layers were
dried with Na.sub.2SO.sub.4, filtered and co-evaporated with
toluene to dryness. The residue was purified by column
chromatography (petroleum ether/Et.sub.2O, 7:1 to 5:1) to yield
compound X as a yellowish oil (631.4 mg, 76%).
[.alpha.].sub.D.sup.21-40.66.degree. (c=0.790, CHCl.sub.3).
Synthesis of Intermediate XI
[0174] To a solution of disaccharide mimic X (139.5 mg, 0.194 mmol)
in THF (5 ml), TBAF (390 .mu.l, 0.390 mmol) was added. After 26 h
additional TBAF (200 .mu.l, 0.200 mmol) was added, and the solution
was continued stirring. The reaction was stopped after 50 h and
concentrated in vacuo (TLC-control: petroleum ether/ethyl acetate,
5:1). The crude product was purified by column chromatography
(petroleum ether/ethyl acetate, 3:1) to afford the unprotected
disaccharide mimic XI as a white solid (95.7 mg, 81%).
[.alpha.].sub.D.sup.21-43.03.degree. (c=1.090, CHCl.sub.3).
Synthesis of Intermediate XII
[0175] Dry CH.sub.2Cl.sub.2 (16 ml) was added to a mixture of the
thioglycoside (562.3 mg, 0.719 mmol), glycosyl acceptor XI (335.6
mg, 0.555 mmol) and activated 4 .ANG. molecular sieves (4 g) under
argon atmosphere. A suspension of DMTST (440.6 mg, 1.706 mmol) and
activated 4 .ANG. molecular sieves (2 g) in CH.sub.2Cl.sub.2 (8 ml)
was prepared in a second flask. Both suspensions were stirred at
room temperature for 4 h, before adding the DMTST suspension via
syringe to the other suspension with some additional
CH.sub.2Cl.sub.2 (1 ml). The reaction was stopped after 63 h
(TLC-control: petroleum ether/Et.sub.20, 1:1), and filtered through
celite, washing with CH.sub.2Cl.sub.2. The filtrate was
successively washed with satd. solution of NaHCO.sub.3 (40 ml) and
water (100 ml). The aqueous layers were three times extracted with
DCM (3.times.60 ml). The combined organic layers were dried with
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
product was purified by repeated column chromatography (petroleum
ether/Et.sub.20, 1:1) to afford tetrasaccharide XII as a white foam
(484.9 mg, 66%). [.alpha.].sub.D.sup.21-52.80 (c=1.050,
CHCl.sub.3).
Synthesis of Product XIII
[0176] A mixture of XII (132.5 mg, 0.100 mmol), Pd(OH).sub.2/C (50
mg), dioxane (3 ml) and water (0.75 ml) was hydrogenated in a
Parr-shaker under 4 bar at r.t. After 20 h the mixture was filtered
through Celite and set up with new Pd(OH).sub.2/C (50 mg) for
another 26 h, after which TLC control indicated completion of the
reaction. The reaction mixture was filtered over Celite and
evaporated to dryness. The residue was redissolved in methanol (4
ml) and sodium methanolate (0.150 mmol in 160 .mu.l MeOH) was
added. After stirring at r.t. for 16 h the reaction was quenched by
addition of acetic acid (17 .mu.l). The mixture was concentrated in
vacuo and purified by preparative, reversed-phase HPLC to afford
compound XIII as a white solid (57.1 mg, 76%).
[.alpha.].sub.D.sup.21-85.02.degree. (c=0.570, MeOH).
Example 2
Synthesis of GlcNac Mimics from Cyclohexenon (FIG. 2)
Synthesis of Intermediate XIV
[0177] 2-Cyclohexenone (9.8 ml, 101 mmol) was dissolved in
CH.sub.2Cl.sub.2 (250 ml) in a light protected flask, then the
solution was cooled to 0.degree. C. Bromine (5.4 ml, 105 mmol) in
CH.sub.2Cl.sub.2 (100 ml) was added via dropping funnel over 35
min. The clear yellow solution was stirred at 0.degree. C. for 2.5
h, then Et.sub.3N (23.1 ml, 166 mmol) in CH.sub.2Cl.sub.2 (20 ml)
was added portion-wise via dropping funnel, causing a color change
from clear yellow to brown with precipitate. The mixture was
stirred at room temperature for 2 h, then stopped. The reaction
mixture was diluted with CH.sub.2Cl.sub.2 (50 ml) and washed twice
with HCl 3% (2.times.50 ml). The aqueous layers were extracted with
CH.sub.2Cl.sub.2 (2.times.25 ml) and the combined organic layers
were washed with a mixture of brine (80 ml) and water (100 ml). The
layers were separated and the aqueous layer was extracted with
CH.sub.2Cl.sub.2 (2.times.50 ml). The combined organic layers were
concentrated in vacuo to afford a brown residue still dissolved in
a few ml of CH.sub.2Cl.sub.2, and was then treated with activated
charcoal and filtered through celite. The clear green mixture was
concentrated to dryness. Recrystallization from hexane/EtOAc (100
ml:few drops) gave offwhite crystals. The crystals were dried in a
desiccator for 12 h affording bromide XIV (11.0 g, 62.8 mmol, 62%).
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz): .delta.=2.07 (m, 2H, H-5),
2.45 (m, 2H, H-4), 2.63 (m, 2H, H-6), 7.42 (t, .sup.3J=4.4 Hz, 1H,
H-3).
Synthesis of Intermediate XV
[0178] (S)-.alpha.,.alpha.-diphenylprolinol (290 mg, 1.14 mmol) was
dissolved in THF (20 ml) in a flame dried, light protected flask,
then under stirring B(OMe).sub.3 (153 .mu.l, 1.37 mmol) was added
via syringe to the solution. The mixture was stirred for 1 h at
room temperature, before BH.sub.3.N,N-diethylaniline (2.00 ml, 11.2
mmol) was added and the resulting solution cooled to -10.degree. C.
A solution of bromide XIV (2.00 g, 11.4 mmol) in THF (15 ml) was
then added over 45 min. The clear yellow mixture was stirred for 3
h at 0.degree. C. After complete conversion of the ketone the
reaction was quenched with HCl (1 M, 20 ml). The resulting mixture
was diluted with CH.sub.2Cl.sub.2 (40 ml) and water (50 ml). After
separation the organic layer was washed with brine (20 ml) and both
aqueous layers were extracted twice with CH.sub.2Cl.sub.2
(2.times.25 ml). The combined organic layers were dried with
Na.sub.2SO.sub.4 and concentrated in vacuo. Chromatographic
purification of the crude product (petroleum ether/Et.sub.2O, 2:1
to 1.5:1) gave XV (1.89 g, 10.7 mmol, 93%) as a colorless oil and
with an optical yield of 96% ee determined by optical rotation and
derivatization with (IR)-(-)-MTPA-Cl. [.alpha.].sub.D.sup.21=+83.0
(c=1.01; CHCl.sub.3); .sup.1H-NMR (CDCl.sub.3, 500.1 MHz):
.delta.=1.59-1.66 (m, 1H, H-5.sub.a), 1.69-1.77 (m, 1H, H-5.sub.b),
1.86-1.97 (m, 2H, H-6.sub.a, H-6.sub.b), 2.00-2.07 (m, 1H,
H-4.sub.a), 2.09-2.16 (m, 1H, H-4.sub.b), 2.26 (m, 1H, OH), 4.20
(m, 1H, H-1), 6.19 (t, .sup.3J=4.0 Hz, 1H, H-3).
Synthesis of Intermediate XVI
[0179] XV (7.33 g, 41.4 mmol) was dissolved in Et.sub.2O (43 ml) in
a flame dried flask equipped with a dropping funnel. tert-BuLi (1.7
M in pentane, 133 mmol) was dropwise added at -78.degree. C. over 1
h and 15 min. After complete addition, the clear yellowish mixture
was stirred for further 1 h and 30 min at -78.degree. C. and was
then warmed up to -20.degree. C. over 3 hrs and 15 min. The
reaction was quenched by addition of satd. solution of NaHCO.sub.3
(50 ml) and stirred for a further hour at room temperature. The
reaction was diluted by addition of water (20 ml) and Et.sub.2O (20
ml). The layers were separated and the aqueous layer extracted
twice with Et.sub.2O (2.times.30 ml). The combined organic layers
were dried with Na.sub.2SO.sub.4 and concentrated in vacuo (>200
mbar) to afford a yellow mixture (still presence of solvent) which
was purified by column chromatography (petroleum ether/Et.sub.2O,
2:1 to 1:1). The product was mostly concentrated in vacuo (>200
mbar), then the rest of the solvent was removed by distillation
under argon with vigreux column to afford alcohol XVI (3.39 g, 34.6
mmol, 85%) as a clear brown oil. [.alpha.].sub.D.sup.21=+117.7
(c=0.95; CHCl.sub.3); .sup.1H-NMR (CDCl.sub.3, 500.1 MHz):
.delta.=1.53-1.64 (m, 3H, H-5.sub.a, H-6.sub.a, OH), 1.68-1.77 (m,
1H, H-5.sub.b), 1.87 (m, 1H, H-6.sub.b), 1.92-2.06 (m, 2H,
H-4.sub.a, H-4.sub.b), 4.19 (s, 1H, H-1), 5.74 (dd, .sup.3J=2.4,
10.0 Hz, 1H, H-2), 5.82 (m, 1H, H-3).
Synthesis of Intermediate XVII
[0180] Alcohol XVI (1.51 g, 15.3 mmol) was stirred in
CH.sub.2Cl.sub.2 (35 ml) at room temperature. Trityl chloride (9.54
g, 34.2 mmol) was added to the mixture, then DBU (5.9 ml, 39.5
mmol) was added via syringe. The brown mixture was stirred for 45
h, then stopped. The reaction mixture was diluted with
CH.sub.2Cl.sub.2 (50 ml) and washed with satd. solution of
NaHCO.sub.3 (50 ml). The layers were separated and the aqueous
layer was extracted twice with CH.sub.2Cl.sub.2 (2.times.25 ml).
The combined organic layers were dried with Na.sub.2SO.sub.4 and
concentrated to dryness. The resulting viscous brown oil was
purified by column chromatography (petroleum ether/toluene, 11:1 to
4:1) affording tritylether XVII (3.72 g, 10.9 mmol, 71%) as a
yellow solid. [.alpha.].sub.D.sup.21=+74.6 (c=1.15; CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz): .delta.=1.31-1.41 (m, 3H,
H-5.sub.a, H-6), 1.68-1.76 (m, 1H, H-5.sub.b), 1.80 (m, 1H,
H-4.sub.a), 1.98 (m, 1H, H-4.sub.b), 4.06 (s, 1H, H-1), 5.03 (m,
1H, H-2), 5.61 (m, 1H, H-3), 7.21-7.54 (m, 15H, 3 C.sub.6H.sub.5);
elemental analysis calcd (%) for C.sub.25H.sub.24O (340.46): C,
88.20, H, 7.10; found: C, 88.01, H, 7.29.
Synthesis of Intermediate Anti-XVIII
[0181] Tritylether XVII (948 mg, 2.79 mmol) was dissolved under
argon atmosphere in CH.sub.2Cl.sub.2 (30 ml) and NaHCO.sub.3 (281
mg, 3.34 mmol) was added. The mixture was cooled to 0.degree. C.
and under stirring m-chloroperbenzoic acid (70%, 960 mg, 5.56 mmol)
was added. After stirring for 1.5 h the reaction temperature was
gradually raised to room temperature and the mixture was stirred
for another 3.5 h. The reaction was diluted with CH.sub.2Cl.sub.2
(50 ml) and transferred to a separation funnel. The excess of
m-chloroperbenzoic acid was destroyed by washing with satd.
solution of Na.sub.2S.sub.2O.sub.3 (2.times.150 ml). The organic
layer was then successively washed with satd. Na.sub.2CO.sub.3
solution (150 ml) and brine (150 ml). The aqueous layers were each
time extracted with CH.sub.2Cl.sub.2 (2.times.50 ml). The combined
organic layers were dried with Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude product was purified by column chromatography
(petroleum ether/EtOAc, 20:1 to 15:1) affording epoxide anti-XVIII
(714 mg, 2.00 mmol, 72%) as colorless solid.
[.alpha.].sub.D.sup.21=+26.6 (c=0.67; CHCl.sub.3); .sup.1H-NMR
(CDCl.sub.3, 500.1 MHz): .delta.=1.02-1.11 (m, 1 H, H-5.sub.a),
1.15-1.22 (m, 1H, H-6.sub.a), 1.37-1.43 (m, 1H, H-5.sub.b), 1.53
(m, 1H, H-6.sub.b), 1.64-1.71 (m, 1H, H-4.sub.a), 1.90 (m, 1H,
H-4.sub.b), 2.25 (m, 1H, H-2). 2.97 (m, 1H, H-3), 3.86 (m, 1H,
H-1), 7.23-7.53 (m, 15H, 3 C.sub.6H.sub.5); elemental analysis
calcd (%) for C.sub.25H.sub.24O.sub.2 (356.46): C, 84.24, H, 6.79;
found: C, 83.86, H, 6.85.
Synthesis of Intermediate XIX
[0182] Copper(I) iodide (499 mg, 2.62 mmol) was dried at high vacuo
at 200.degree. C. for 30 minutes, then flushed with argon and
suspended in dry diethylether (10 ml). After cooling to -20.degree.
C. MeLi (1.6 M in ether, 3.26 ml, 5.22 mmol) was slowly added and
the solution was stirred for 15 minutes. A solution of epoxide
anti-XVIII (310 mg, 0.870 mmol) in diethylether (7 ml) was added to
the cuprate. After stirring for 30 minutes at -20.degree. C. the
reaction mixture was slowly brought to room temperature and stirred
for one week. The reaction was diluted with tert-butyl methyl ether
(10 ml) and quenched at 0.degree. C. with satd. solution of
NaHCO.sub.3 (10 ml). The reaction mixture was further diluted and
extracted with tert-butyl methyl ether and satd. solution of
NaHCO.sub.3 (each 20 ml). The aqueous layer was extracted twice
with tert-butyl methyl ether (2.times.50 ml). The combined organic
layers were dried with Na.sub.2SO.sub.4 and concentrated. The
residue was purified by flash chromatography (petroleum
ether/EtOAc/Et.sub.3N, 13:1:0.07) to yield XIX (206 mg, 64%) as
yellowish resin. [.alpha.].sub.D.sup.21=-57.6 (c=0.52; CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz): .delta.=0.78 (m, 1H,
H-5.sub.a), 0.94 (m, 1H, H-4.sub.a), 1.00 (d, .sup.3J=6.4 Hz, 3H,
CH.sub.3), 1.17 (m, 1H, H-3), 1.32 (m, 1H, H-6.sub.a), 1.40 (m, 1H,
H-5.sub.b), 1.46-1.49 (m, 2H, H-4.sub.b, H-6.sub.b), 2.67 (s, 1H,
OH), 2.83 (ddd, .sup.3J=4.1, 8.6, 11.1 Hz, 1H, H-1), 3.32 (t,
.sup.3J=9.2 Hz, 1H, H-2), 7.21-7.30, 7.49-7.50 (m, 15H, 3
C.sub.6H.sub.5); elemental analysis calcd (%) for
C.sub.26H.sub.28O.sub.2 (372.51): C, 83.83, H, 7.58; found: C,
83.51, H, 7.56.
Synthesis of Intermediate XX
[0183] A solution of Br.sub.2 (43 .mu.l, 0.837 mmol) in
CH.sub.2Cl.sub.2 (1 ml) was added dropwise at 0.degree. C. to a
solution of ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (349 mg,
0.729 mmol) in CH.sub.2Cl.sub.2 (2 ml). After stirring for 50 min
at 0.degree. C., cyclohexene (100 .mu.l) was added and the solution
stirred for another 20 min. The mixture was dropwise added to a
solution of XIX (208 mg, 0.558 mmol) and Et.sub.4NBr (154 mg, 0.733
mmol) in DMF/CH.sub.2Cl.sub.2 (10 ml, 1:1) which has been stirred
with activated 3 .ANG. molecular sieves (850 mg) for 2 h. The
mixture was stirred for 14 h at room temperature. The reaction was
quenched with pyridine (1 ml) and filtered over celite with
addition of CH.sub.2Cl.sub.2 (20 ml). The solution was washed with
brine (40 ml) and the aqueous layer was extracted with
CH.sub.2Cl.sub.2 (3.times.30 ml). The combined organic phases were
dried with Na.sub.2SO.sub.4, the solvent was removed azeotropic
with toluene, and the residue was purified by flash chromatography
(petroleum ether/toluene/ethyl acetate/Et.sub.3N, 20:5:1:0.26) to
afford 254 mg (58%, 0.322 mmol) of XX as colorless foam.
[.alpha.].sub.D.sup.21=-36.4 (c=0.51; CHCl.sub.3); .sup.1H-NMR
(CDCl.sub.3, 500.1 MHz): .delta.=0.81 (d, .sup.3J=6.5 Hz, 3H, Fuc
H-6), 1.05 (m, 1H, H-6.sub.a), 1.18 (d, .sup.3J=7.6 Hz, 3H,
CH.sub.3), 1.15-1.28 (m, 2H, H-4.sub.a, H-5.sub.a), 1.34 (m, 1H,
H-6.sub.b), 1.75 (m, 1H, H-4.sub.b), 1.85-1.90 (m, 2H, H-3,
H-5.sub.b), 2.91 (m, 1H, H-2), 3.52 (m, 1H, Fuc H-4), 3.64 (m, 1H,
Fuc H-5), 3.76 (dd, .sup.3J=2.7, 10.1 Hz, 1H, Fuc H-3), 3.81 (m,
1H, H-1), 3.88 (dd, .sup.3J=3.6, 10.1 Hz, 1H, Fuc H-2), 4.54 (m,
1H, CH.sub.2Ph), 4.61 (d, 1H, Fuc H-1), 4.61, 4.64, 4.65, 4.77,
4.92 (5 m, 5H, 3 CH.sub.2Ph), 7.17-7.34, 7.48-7.50 (m, 30H, 6
C.sub.6H.sub.5).
Synthesis of Intermediate XXI
[0184] To a stirred solution of tritylether XX (241 mg, 0.305 mmol)
in CH.sub.2Cl.sub.2 (4 ml), ZnBr.sub.2 (208 mg, 0.924 mmol) and
triethylsilane (55 .mu.l, 0.344 mmol) was added. The reaction was
quenched after 8 h by adding 100 .mu.l water. CH.sub.2Cl.sub.2 (10
ml) was added and the reaction mixture extracted with satd.
solution of NaHCO.sub.3 (30 ml). After separation the aqueous layer
was extracted twice with DCM (2.times.20 ml). The combined organic
layers were washed with satd. solution of NaHCO.sub.3 (50 ml) and
the aqueous layer was extracted twice with DCM (2.times.50 ml). The
combined organic layers were dried with Na.sub.2SO.sub.4 and
concentrated in vacuo. Chromatographic purification of the crude
product (petroleum ether/toluene/ethyl acetate, 5:5:1) gave 140 mg
(84%, 0.256 mmol) of XXI as yellowish solid.
[.alpha.].sub.D.sup.21=-35.0 (c=0.45; CHCl.sub.3); .sup.1H-NMR
(CDCl.sub.3, 500.1 MHz): .delta.=0.98 (m, 1H, H-4.sub.a), 1.08 (d,
.sup.3J=6.4 Hz, 3H, CH.sub.3), 1.16 (d, .sup.3J=6.5 Hz, 3H, Fuc
H-6), 1.22-1.30 (m, 2H, H-5.sub.a, H-6.sub.a), 1.51 (m, 1H, H-3),
1.61-1.67 (m, 2H, H-4.sub.b, H-5.sub.b), 2.00 (m, 1 H, H-6.sub.b),
2.87 (t, .sup.3J=9.3 Hz, 1H, H-2), 3.37 (m, 1H, H-1), 3.70 (m, 1H,
Fuc H-4), 3.97 (dd, .sup.3J=2.7, 10.2 Hz, 1H, Fuc H-3), 4.10-4.14
(m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.70, 4.76, 4.77, 4.86, 4.99 (6 m,
6H, 3 CH.sub.2Ph), 5.00 (d, 1H, Fuc H-1), 7.25-7.39 (m, 15H, 3
C.sub.6H.sub.5); elemental analysis calcd (%) for
C.sub.34H.sub.42O.sub.6 (546.69): C, 74.70, H, 7.74; found: C,
74.68, H, 7.80.
Synthesis of Intermediate XXII
[0185] Dry CH.sub.2Cl.sub.2 (8 ml) was added to a mixture of the
thioglycoside (254 mg, 0.325 mmol), the glycosyl acceptor XXI (137
mg, 0.251 mmol) and activated 4 .ANG. molecular sieves (2 g) under
argon atmosphere. A suspension of DMTST (206 mg, 0.798 mmol) and
activated 4 .ANG. molecular sieves (1 g) in CH.sub.2Cl.sub.2 was
prepared in a second flask. Both suspensions were stirred at room
temperature for 4 h, before adding the DMTST suspension via syringe
to the other suspension. The reaction was stopped after 43 h and
filtered through celite, washing with CH.sub.2Cl.sub.2. The
filtrate was successively washed with satd. solution of NaHCO.sub.3
(20 ml) and water (60 ml). The aqueous layers were each time
extracted with DCM (3.times.30 ml). The combined organic layers
were dried with Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude product was purified by column chromatography (petroleum
ether/toluene/ethyl acetate, 7:7:1 to 5:5:1) to afford 187 mg (59%,
0.148 mmol) of XXII as colorless foam. [.alpha.].sub.D.sup.21=-51.0
(c=0.51; CHCl.sub.3); .sup.1H-NMR (CDCl.sub.3, 500.1 MHz):
.delta.=0.45-1.46 (m, 19H, CyCH.sub.2, MeCy), 1.04 (d, .sup.3J=6.3
Hz, 3H, CH.sub.3), 1.44 (d, .sup.3J=6.4 Hz, 3H, Fuc H-6), 1.86 (m,
1H, MeCy), 3.21 (t, .sup.3J=9.1 Hz, 1H, H-2), 3.48 (m, 1H, H-1),
3.51 (s. 1H, Fuc H-4), 3.82 (dd, .sup.3J=3.3, 9.9 Hz, 1H, Gal H-3),
3.91 (m, 1H, Gal H-5), 4.02 (dd, .sup.3J=3.3, 10.3 Hz, 1H, Fuc
H-2), 4.05 (dd, .sup.3J=2.3, 10.3 Hz, 1H, Fuc H-3), 4.12 (dd,
.sup.3J=4.6, 7.9 Hz, 1H, Lac H-2), 4.24 (dd, .sup.3J=7.2 Hz,
.sup.2J=11.4 Hz, 1H, Gal H-60, 4.26 (m, 1H, CH.sub.2Ph), 4.38 (dd,
.sup.3J=5.7 Hz, .sup.2J=11.4 Hz, 1H, Gal H-6.sub.b), 4.51 (m, 1H,
CH.sub.2Ph), 4.54 (d, .sup.3J=8.2 Hz, 1H, Gal H-1), 4.63, 4.67,
4.74, 4.77 (4 m, 4H, 2 CH.sub.2Ph), 4.88 (m, 1H, Fuc H-5), 5.05 (m,
1H, CH.sub.2Ph), 5.06 (d, .sup.3J=3.5 Hz, 1H, Fuc H-1), 5.11 (m,
1H, CH.sub.2Ph), 5.60 (m, 1H, Gal H-2), 5.84 (m, 1H, Gal H-4),
7.17-7.34, 7.42-7.46, 7.52-7.58, 8.03-8.12 (m, 35 H, 7
C.sub.6H.sub.5); elemental analysis calcd (%) for
C.sub.77H.sub.84O.sub.16 (1265.48): C, 73.08, H, 6.69; found: C,
73.16, H, 6.76.
Synthesis of Product XXIII
[0186] Pd/C (50 mg, 10% Pd) was suspended under argon atmosphere in
ethanol (3 ml) with a catalytic amount of acetic acid. Compound
XXII (101 mg, 79.8 .mu.mol) was added and the resulting mixture was
hydrogenated under 70 psi at room temperature. After 1 day another
50 mg of Pd/C were added and hydrogenation was continued for
another 5 days. The reaction was quenched with CH.sub.2Cl.sub.2 and
filtered on celite, washing with methanol. The filtrate was
concentrated under vacuum, redissolved in methanol/water (3:1, 4
ml) and lithium hydroxide (100 mg, 4.18 mmol) was added. After 2
days stirring the mixture was neutralized with Dowex 50.times.8
(H.sup.+), filtered through a Dowex 50 ion exchanger column
(Na.sup.+ form) and concentrated in vacuo. The residue was purified
by column chromatography (CH.sub.2Cl.sub.2/methanol/water, 5:1:0.1
to 5:2.5:0.25), followed by Sephadex G15 column and lyophilization
from dioxane to give 36.5 mg (74%, 59.4 .mu.mol) of XXIII as
colorless foam. [.alpha.].sub.D.sup.21=-84.8 (c=0.32; MeOH);
.sup.1H-NMR (MeOD, 500.1 MHz): .delta.=0.87-1.00 (m, 2H,
CyCH.sub.2, MeCy), 1.04-1.38 (m, 6H, CyCH.sub.2, MeCy), 1.13 (d,
.sup.3J=6.3 Hz, 3H, CH.sub.3), 1.20 (d, .sup.3J=6.5 Hz, 3H, Fuc
H-6), 1.55-1.74 (m, 10H, CyCH.sub.2, MeCy), 1.92 (m, 1H), 2.13 (m,
1H, MeCy), 3.20 (t, .sup.3J=9.3 Hz, 1 H, H-2), 3.24 (dd,
.sup.3J=2.8, 9.3 Hz, 1H, Gal H-3), 3.42 (m, 1H, Gal H-5), 3.62-3.68
(m, 3H, Gal H-2, Gal H-6.sub.a, H-1), 3.70-3.75 (m, 3H, Fuc H-2,
Fuc H-4, Gal H-6.sub.b), 3.85 (dd, .sup.3J=3.3, 10.3 Hz, 1H, Fuc
H-3), 3.88 (m, 1H, Gal H-4) 4.07 (dd, .sup.3J=3.1, 9.3 Hz, 1H, Lac
H-2), 4.29 (d, .sup.3J=7.8 Hz, 1H, Gal H-1), 4.89 (m, 1H, Fuc H-5),
5.00 (d, .sup.3J=3.9 Hz, 1H, Fuc H-1); elemental analysis calcd (%)
for C.sub.28H.sub.47NaO.sub.13. 1 H.sub.2O (614.65+18.02): C,
53.16, H, 7.81; found: C, 53.22, H, 7.91.
Example 3
{(1R,2R,3S)-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-
-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-galactopy-
ranoside (A-VIII; FIG. 3)
[0187] General Procedure a for Nucleophilic Opening of Epoxide A-I
with Cuprate Reagents
[0188] CuCN (3.81 mmol) was dried in vacuo at 150.degree. C. for 30
min, suspended in dry THF (10 mL) and cooled to -78.degree. C. A
solution of the appropriate organo lithium compound (7.63 mmol) was
slowly added via syringe and the temperature was raised over a
period of 30 min to -20.degree. C. and the mixture stirred at this
temperature for 10 min. The mixture was cooled to -78.degree. C.
followed by the addition of freshly distilled BF.sub.3 etherate
(1.53 mmol) in THF (2 mL). After stirring for 20 min, epoxide A-I
(0.761 mmol) dissolved in THF (8 mL) was added. The reaction was
slowly warmed to -50.degree. C. over 5 h and then stirred at this
temperature for 24 h. After slowly warming the reaction to
-30.degree. C. over another 21 h the reaction was quenched with a
25% aq. NH.sub.3/satd. NH.sub.4Cl (1:9, 20 mL) solution. The
mixture was transferred with Et.sub.2O (30 mL) into a separation
funnel and extracted with additional 25% aq. NH.sub.3/satd.
NH.sub.4Cl (1:9, 30 mL) solution. The layers were separated and the
organic layer was washed with brine (50 mL). The aqueous layers
were extracted with Et.sub.2O (2.times.30 mL). The combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
in vacuo. The crude product was purified by column chromatography
(petroleum ether/Et.sub.2O, 20:1 to 13:1, +1% Et.sub.3N) to afford
the corresponding GlcNAc mimic.
General Procedure B for .alpha.-Fucosylation and Detritylation
[0189] A solution of Br.sub.2 (0.837 mmol) in CH.sub.2Cl.sub.2 (1
mL) was added dropwise at 0.degree. C. to a solution of ethyl
2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (A-III, 0.729 mmol) in
CH.sub.2Cl.sub.2 (2 mL). After stirring for 50 min at 0.degree. C.,
cyclohexene (100 .mu.L) was added and the solution stirred for
another 20 min. The mixture was added dropwise to a solution of the
appropriate GlcNAc mimic (0.558 mmol) and Et.sub.4NBr (0.733 mmol)
in DMF/CH.sub.2Cl.sub.2 (10 mL, 1:1), which has been stirred with
activated 3 .ANG. molecular sieves (850 mg) for 2 h. The mixture
was stirred for 14 h at r.t. The reaction was quenched with
pyridine (1 mL) and filtered over celite with addition of
CH.sub.2Cl.sub.2 (20 mL). The solution was washed with brine (40
mL) and the aqueous layer was extracted with CH.sub.2Cl.sub.2
(3.times.30 mL). The combined organic phases were dried with
Na.sub.2SO.sub.4, filtered and the solvents were removed
azeotropically with toluene. The residue was purified by flash
chromatography (petroleum ether/diethyl ether, 12:1 to 7:1, +1%
Et.sub.3N) to afford the fucosylated tritylether. To a stirred
solution of the tritylether (0.305 mmol) in CH.sub.2Cl.sub.2 (4
mL), ZnBr.sub.2 (0.924 mmol) and triethylsilane (0.344 mmol) were
added. The reaction was quenched after 8 h by adding water (100
.mu.L). CH.sub.2Cl.sub.2 (10 mL) was added and the reaction mixture
extracted with satd. aqueous NaHCO.sub.3 (30 mL). The aqueous layer
was extracted with DCM (2.times.20 mL). The combined organic layers
were washed with satd. aqueous NaHCO.sub.3 (50 mL) and the aqueous
layer was extracted with DCM (2.times.50 mL). The combined organic
layers were dried with Na.sub.2SO.sub.4, filtered and concentrated
in vacuo. Chromatographic purification of the crude product
(petroleum ether/toluene/ethyl acetate, 7:7:1 to 4:4:1) afforded
the corresponding disaccharide mimic.
General Procedure C for DMTST Promoted Glycosylations
[0190] A solution of the thioglycoside A-VI (0.292 mmol) and the
appropriate glycosyl acceptor (0.225 mmol) in dry CH.sub.2Cl.sub.2
(8 mL) was added via syringe to activated 3 .ANG. molecular sieves
(2 g) under argon. A suspension of dimethyl(methylthio)sulfonium
triflate (DMTST) (0.685 mmol) and activated 3 .ANG. molecular
sieves (1 g) in CH.sub.2Cl.sub.2 (4 mL) was prepared in a second
flask. Both suspensions were stirred at r.t. for 4 h, then the
DMTST suspension was added via syringe to the other suspension with
some additional CH.sub.2Cl.sub.2 (2 ml). The reaction was stopped
after 2 d, filtered through celite and the celite washed with
CH.sub.2Cl.sub.2 (10 mL). The filtrate was successively washed with
satd. aqueous NaHCO.sub.3 (25 mL) and water (40 mL). The aqueous
layers were extracted with CH.sub.2Cl.sub.2 (3.times.25 mL). The
combined organic layers were dried with Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. The crude product was purified by column
chromatography (petroleum ether/toluene/ethyl acetate, 10:10:1 to
5:5:1) to afford the corresponding tetrasaccharide mimic as a
colorless foam.
General Procedure D for Deprotection with Pd(OH).sub.2/C and Sodium
Methoxide.
[0191] Pd(OH).sub.2/C (50 mg, 10% Pd) was suspended under argon in
dioxane/H.sub.2O (4:1, 3.75 mL). The appropriate protected compound
(77.7 .mu.mol) was added and the resulting mixture was hydrogenated
under 70 psi at r.t. After 24 h the mixture was filtered through
celite and reacted with fresh Pd(OH).sub.2/C (50 mg) for additional
48 h, until TLC control indicated completion of the reaction. The
reaction mixture was filtered through celite and evaporated to
dryness. The residue was redissolved in methanol (5 mL) and sodium
methoxide (0.194 mmol in 190 .mu.l MeOH) was added. After stirring
at r.t. for 16 h the reaction was quenched by addition of acetic
acid (22 .mu.L). The mixture was concentrated in vacuo and purified
by preparative, reversed-phase HPLC to afford the corresponding
antagonists as colorless solids.
(1R,2R,3R)-3-Ethenyl-1-O-triphenylmethyl-cyclohexane-1,2-diol
(A-II)
[0192] A vinyl lithium solution was generated in situ by treating a
solution of tetravinyl tin (409 .mu.L, 2.25 mmol) in THF (3 mL)
with nBuLi (2.5 M in hexane, 3.35 mL, 8.38 mmol) during 30 min at
0.degree. C. CuCN (373 mg, 4.16 mmol) in THF (8 mL) was treated
with the vinyl lithium solution and BF.sub.3 etherate (209 .mu.L,
1.66 mmol) in THF (1.5 mL) according to general procedure A.
Epoxide A-I (296 mg, 0.830 mmol) in THF (8 mL) was slowly added and
the reaction slowly warmed to -30.degree. C. (-78.degree. C.: 15
min; -78.degree. C. to -50.degree. C.: 1.5 h; -50.degree.: 13 h;
-50.degree. C. to -30.degree. C.: 1.5 h; -30.degree. C.: 24 h).
Work-up and purification according to general procedure A yielded
A-II (258 mg, 81%) as a yellowish resin.
[0193] [.alpha.].sub.D.sup.21=-33.7 (c=0.53, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.84 (m, 1H,
H-5.sub.a), 1.15 (m, 1H, H-4.sub.a), 1.32 (m, 1H, H-6.sub.a),
1.43-1.55 (m, 3H, H-5.sub.b, H-6.sub.b, H-4.sub.b), 1.81 (m, 1H,
H-3), 2.66 (s, 1H, OH), 2.91 (ddd, .sup.3J=3.9, 8.6, 11.3 Hz, 1H,
H-1), 3.51 (t, .sup.3J=9.3 Hz, 1H, H-2), 5.02 (A of ABX,
.sup.3J.sub.A,X=10.4 Hz, .sup.2J.sub.A,B=1.7 Hz,
.sup.3J.sub.A,3=0.7 Hz, 1H, vinyl H.sub.A), 5.04 (B of ABX,
.sup.3J.sub.B,X=17.2 Hz, .sup.2J.sub.A,B=1.7 Hz,
.sup.3J.sub.X,3=1.1 Hz, 1H, vinyl H.sub.B), 5.83 (X of ABX,
.sup.3J.sub.A,X=10.4 Hz, .sup.3J.sub.B,X=17.2 Hz,
.sup.3J.sub.X,3=7.6 Hz, 1H, vinyl H.sub.X), 7.21-7.31, 7.48-7.50 (2
m, 15H, 3 C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz)
.delta.: 23.18 (C-5), 30.39 (C-4), 32.21 (C-6), 47.30 (C-3), 76.74
(C-2), 78.53 (C-1), 114.77 (vinyl C), 127.11, 127.77, 128.75,
145.07 (18C, 3C.sub.6H.sub.5), 140.57 (vinyl C); IR (film on NaCl)
v: 3577 (m, OH), 3059 (m), 2932 (vs), 2860 (s), 1641 (vw), 1597
(vw), 1489 (s), 1448 (s), 1278 (m), 1225 (m), 1152 (w), 1064 (vs),
991 (s), 915 (m) cm.sup.-1; elemental analysis calcd (%) for
C.sub.27H.sub.28O.sub.2 (384.51): C, 84.34, H, 7.34; found: C,
84.15, H, 7.33.
[(1R,2R,3R)-3-Ethenyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy--
.alpha.-L-galactopyranoside (A-IV)
[0194] According to general procedure B, A-III (205 mg, 0.428 mmol)
in CH.sub.2Cl.sub.2 (1.5 mL) was treated with a solution of
Br.sub.2 (25.5 .mu.L, 0.496 mmol) in CH.sub.2Cl.sub.2 (1 mL) for 40
min at 0.degree. C. After destroying the excess of bromine, the
fucosyl bromide solution was added to a solution of A-II (126 mg,
0.329 mmol) and Et.sub.4NBr (90.8 mg, 0.432 mmol) in
DMF/CH.sub.2Cl.sub.2 (6 mL, 1:1), which has been stirred with
activated 3 .ANG. molecular sieves (500 mg) for 4 h. The reaction
was stirred for 67 h at r.t. and then quenched with pyridine (1
mL). Work-up and purification according to general procedure B
yielded the tritylether (213 mg). To a stirred solution of the
tritylether in CH.sub.2Cl.sub.2 (4 mL), ZnBr.sub.2 (179 mg, 0.793
mmol) and triethylsilane (63 .mu.L, 0.397 mmol) were added. The
reaction was quenched after 2 h by adding H.sub.2O (100 .mu.L).
Work-up and purification according to general procedure B yielded
A-IV (110 mg, 60% over two steps) as a colorless solid.
[0195] [.alpha.].sub.D.sup.21=-22.1 (c=0.52, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 1.15 (d,
.sup.3J.sub.F6,F5=6.5 Hz, 3H, Fuc H-6), 1.17 (m, 1H, H-4.sub.a),
1.26-1.30 (m, 2H, H-5.sub.a, H-6.sub.a), 1.72 (m, 1H, H-5.sub.b),
1.78 (m, 1H, H-4.sub.b), 2.02 (m, 1H, H-6.sub.b), 2.13 (m, 1H,
H-3), 3.04 (t, .sup.3J=9.5 Hz, 1H, H-2), 3.45 (m, 1H, H-1), 3.69
(m, 1H, Fuc H-4), 3.98 (dd, .sup.3J.sub.F3,F4=2.6 Hz,
.sup.3J.sub.F2,F3=10.1 Hz, 1H, Fuc H-3), 4.10 (dd,
.sup.3J.sub.F1,F2=3.6 Hz, .sup.3J.sub.F2,F3=10.1 Hz, 1H, Fuc H-2),
4.12 (m, 1H, Fuc H-5), 4.65, 4.70, 4.76, 4.78, (4 m, 4H, 2
CH.sub.2Ph), 4.85 (m, 2H, CH.sub.2Ph, vinyl H), 4.98 (m, 1H, vinyl
H), 4.99 (m, 1H, CH.sub.2Ph), 5.03 (d, .sup.3J.sub.F1,F2=3.6 Hz,
1H, Fuc H-1), 6.25 (m, 1H, vinyl H), 7.27-7.40 (m, 15H, 3
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
16.55 (Fuc C-6), 22.81 (C-5), 29.67 (C-4), 32.39 (C-6), 44.33
(C-3), 67.56 (Fuc C-5), 72.97, 73.01 (CH.sub.2Ph, C-1), 73.38,
74.85 (2 CH.sub.2Ph), 76.41 (Fuc C-2), 77.54 (Fuc C-4), 78.86 (Fuc
C-3), 90.26 (C-2), 97.98 (Fuc C-1), 113.46 (vinyl C), 127.43,
127.48, 127.53, 127.63, 127.82, 128.23, 128.36 (18C, 3
C.sub.6H.sub.5), 140.43 (vinyl C), IR (KBr) v: 3429 (s, OH), 3065
(w), 3031 (w), 2932 (s), 2866 (s), 1636 (vw), 1497 (w), 1454 (m),
1348 (m), 1308 (w), 1246 (vw), 1212 (w), 1161 (s), 1138 (s), 1101
(vs), 1064 (vs), 1027 (vs), 953 (m), 911 (w) cm.sup.-1; elemental
analysis calcd (%) for C.sub.35H.sub.42O.sub.6 (558.70): C, 75.24,
H, 7.58; found: C, 74.91, H, 7.55.
[(1R,2R,3S)-3-Ethyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-.a-
lpha.-L-galactopyranoside (A-V)
[0196] A solution of A-IV (90.0 mg, 0.161 mmol) in THF (4 mL) was
added to Pd/C (45.2 mg, 10% Pd) under argon. The mixture was
hydrogenated under atmospheric pressure at r.t. After 30 min the
reaction was filtered through celite, concentrated under reduced
pressure and purified by column chromatography (toluene/petroleum
ether/ethyl acetate, 7:7:1 to 5:5:1) to yield A-V (69.8 mg, 77%) as
a colorless solid.
[0197] [.alpha.].sub.D.sup.21=-37.2 (c=0.50, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.78 (t, .sup.3J=7.5
Hz, 3H, CH.sub.2CH.sub.3), 0.88 (m, 1H, H-4.sub.a), 1.06-1.26 (m,
3H, CH.sub.2CH.sub.3, H-5.sub.a, H-6.sub.a), 1.16 (d,
.sup.3J.sub.F5,F6=6.5 Hz, 3H, Fuc H-6), 1.30 (m, 1H, H-3), 1.67 (m,
1 H, H-5.sub.b), 1.79 (m, 1H, H-4.sub.b), 1.99-2.07 (m, 2H,
H-6.sub.b, CH.sub.2CH.sub.3), 2.96 (dd, .sup.3J=8.6, 10.2 Hz, 1H,
H-2), 3.38 (ddd, .sup.3J=4.8, 8.5, 10.6 Hz, 1H, H-1), 3.70 (m, 1H,
Fuc H-4), 3.98 (dd, .sup.3J.sub.F3,F4=2.7 Hz,
.sup.3J.sub.F3,F2=10.2 Hz, 1H, Fuc H-5), 4.10-4.14 (m, 2H, Fuc H-2,
Fuc H-5), 4.66, 4.70, 4.77, 4.80, 4.84 (5 m, 5H, CH.sub.2Ph),
4.89-5.00 (m, 2 H, Fuc H-1, CH.sub.2Ph), 7.27-7.40 (m, 15H, 3
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
10.99 (CH.sub.2CH.sub.3), 16.60 (Fuc C-6), 23.09 (C-5), 24.17
(CH.sub.2CH.sub.3), 29.50 (C-4), 32.60 (C-6), 42.64 (C-3), 67.48
(Fuc C-5), 72.83, 73.13, 73.47 (C-1, 2 CH.sub.2Ph), 74.84
(CH.sub.2Ph), 76.32 (Fuc C-2), 77.37 (Fuc C-4), 78.86 (Fuc C-3),
91.07 (C-2), 98.31 (Fuc C-1), 127.40, 127.46, 127.50, 127.64,
127.80, 128.21, 128.33, 128.39, 138.31, 138.39, 138.70 (18C, 3
C.sub.6H.sub.5); HR-MS (ESI) m/z: calcd for
C.sub.35H.sub.44NaO.sub.6 [M+Na].sup.+: 583.3030; found: 583.3018
(2.1 ppm).
{(1R,2R,3S)-2-[(2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyranosyl)oxy-
]-3-ethyl-cyclohex-1-yl}2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl--
2-cyclohexyl-ethyl]-.beta.-D-galactopyranoside (A-VII)
[0198] According to general procedure C, thioglycoside A-VI (112
mg, 0.144 mmol) and glycosyl acceptor A-V (61.6 mg, 0.110 mmol) in
dry CH.sub.2Cl.sub.2 (4 mL) were added via syringe to activated 3
.ANG. molecular sieves (1 g). A suspension of DMTST (87.0 mg, 0.337
mmol) and activated 3 .ANG. molecular sieves (500 mg) in
CH.sub.2Cl.sub.2 (2 mL) was prepared in a second flask. Both
suspensions were stirred at r.t. for 4 h, then the DMTST suspension
was added via syringe to the other suspension with some additional
CH.sub.2Cl.sub.2 (1 mL). The reaction was stopped after 49.5 h and
work-up and purification according to general procedure C afforded
A-VII (110 mg, 78%) as a colorless foam.
[0199] [.alpha.].sub.D.sup.21=-51.5 (c=0.42, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.45-1.61 (m, 20H,
CyCH.sub.2, EtCy), 0.75 (t, .sup.3J=7.3 Hz, 3H, CH.sub.2CH.sub.3),
1.41 (d, .sup.3J.sub.F5,F6=6.4 Hz, 3H, Fuc H-6), 1.84 (m, 1H,
H-6.sub.b), 1.92 (m, 1H, CH.sub.2CH.sub.3), 3.31 (t, .sup.3J=8.7
Hz, 1H, H-2), 3.49-3.52 (m, 2H, H-1, Fuc H-4), 3.82 (dd,
.sup.3J.sub.G3,G4=3.2 Hz, .sup.3J.sub.G2,G3=9.8 Hz, 1H, Gal H-3),
3.92 (m, 1H, Gal H-5), 3.99-4.05 (m, 2H, Fuc H-2, Fuc H-3), 4.12
(dd, .sup.3J=4.6, 7.9 Hz, 1H, Lac H-2), 4.25 (dd,
.sup.3J.sub.G5,G6a=7.2 Hz, .sup.3J.sub.G6a,G6b=11.4 Hz, 1H, Gal
H-6.sub.a), 4.28 (m, 1H, CH.sub.2Ph), 4.39 (dd,
.sup.3J.sub.G5,G6b=5.7 Hz, .sup.3J.sub.G6a,G6b=11.4 Hz, 1H, Gal
H-6.sub.b), 4.51-4.55 (m, 2H, CH.sub.2Ph, Gal H-1), 4.63, 4.65,
4.75, 4.78 (4 m, 4H, CH.sub.2Ph), 4.81 (m, 1H, Fuc H-5), 4.98 (d,
.sup.3J.sub.F1,F2=2.8 Hz, 1H, Fuc H-1), 5.04, 5.11 (2 m, 2H,
CH.sub.2Ph), 5.60 (m, 1H, Gal H-2), 5.84 (m, 1 H, Gal H-4),
7.17-7.33, 7.42-7.46, 7.52-7.58, 8.04-8.12 (4 m, 35H, 7
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
10.94 (CH.sub.2CH.sub.3), 16.82 (Fuc C-6), 23.18
(CH.sub.2CH.sub.3), 22.11, 25.45, 25.71, 26.07, 27.89, 30.41,
32.60, 33.19, 33.40, 40.49 (10C, EtCy, CyCH.sub.2), 44.71 (0-3),
62.50 (Gal C-6), 66.35 (Fuc C-5), 66.64 (CH.sub.2Ph), 70.17 (Gal
C-4), 71.40 (Gal C-5), 72.07 (CH.sub.2Ph), 72.17 (Gal C-2), 74.29,
74.91 (2 CH.sub.2Ph), 76.42 (Fuc C-2), 78.06 (Gal C-3), 78.38 (Lac
C-2), 79.22, 79.27 (Fuc C-4, C-2), 79.77 (Fuc C-3), 80.95 (C-1),
97.96 (Fuc C-1), 100.05 (Gal C-1), 126.94, 127.06, 127.21, 127.39,
127.77, 128.05, 128.10, 128.38, 128.44, 128.50, 128.54, 129.66,
129.93, 133.03, 133.17, 133.27, 135.40, 138.64, 139.01, 139.17
(42C, 7 C.sub.6H.sub.5), 164.58, 166.11, 166.22, 172.48 (4
C.dbd.O); elemental analysis calcd (%) for C.sub.78H.sub.86O.sub.16
(1279.51)+1/2 H.sub.2O: C, 72.20, H, 6.84; found: C, 72.37, H,
6.82; HR-MS (ESI) m/z: calcd for
C.sub.78H.sub.86NaO.sub.16[M+Na].sup.+: 1301.5808; found: 1301.5855
(3.6 ppm).
{(1R,2R,3S)-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-
-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-galactopy-
ranoside (A-VIII; FIG. 3)
[0200] A-VII (38.2 mg, 29.9 .mu.mol) was hydrogenated with
Pd(OH).sub.2/C (50 mg, 10% Pd) in dioxane/H.sub.2O (4:1, 3.75 mL)
according to general procedure D. After 24 h the reaction mixture
was filtered through celite and evaporated to dryness. The residue
was redissolved in methanol (5 mL) and sodium methoxide (74.6
.mu.mol in 73 .mu.l MeOH) was added. After stirring at r.t. for 16
h the reaction was quenched by addition of acetic acid (8.5 .mu.L).
The mixture was concentrated in vacuo and purified by preparative,
reversed-phase HPLC to afford A-VIII (16.3 mg, 77%) as a colorless
solid.
[0201] [.alpha.].sub.D.sup.21=-89.3 (c=0.47, MeOH); .sup.1H-NMR
(MeOD, .delta.00.1 MHz) .delta.: 0.55-1.69 (m, 20H, CyCH.sub.2,
EtCy), 0.83 (t, .sup.3J=7.3 Hz, 3H, CH.sub.2CH.sub.3), 1.32 (d,
.sup.3J=6.6 Hz, 3H, Fuc H-6), 1.90 (m, 1H, CH.sub.2CH.sub.3), 1.99
(m, 1H, H-6.sub.b), 3.24 (t, .sup.3J=8.9 Hz, 1H, H-2), 3.57 (m, 1H,
Gal H-5), 3.62 (m, 1H, H-1), 3.67 (dd, .sup.3J.sub.G3,G4=3.0 Hz,
.sup.3J.sub.G2,G3=9.8 Hz, 1H, Gal H-3), 3.70-3.75 (m, 3H, Gal
H-6.sub.a, Fuc H-2, Fuc H-4), 3.79 (dd, .sup.3J.sub.G5,G6b=6.9 Hz,
.sup.2J.sub.G6a,G6b=11.3 Hz, 1H, Gal H-6.sub.b), 3.86 (dd,
.sup.3J.sub.F3,F4=3.3 Hz, .sup.3J.sub.F2,F3=10.3 Hz, 1H, Fuc H-3),
3.97 (m, 1H, Gal H-4), 4.07 (dd, .sup.3J=3.0, 9.8 Hz, 1H, Lac H-2),
4.67 (d, .sup.3J.sub.G1,G2=8.1 Hz, 1H, Gal H-1), 4.90 (m, 1H, Fuc
H-5), 4.91 (m, 1H, Fuc H-1), 5.43 (dd, .sup.3J.sub.G1,G2=8.3 Hz,
.sup.3J.sub.G2,G3=9.4 Hz, 1H, Gal H-2), 7.49-7.52, 7.61-7.64,
8.08-8.09 (3 m, 5H, C.sub.6H.sub.5); .sup.13C-NMR (MeOD, 125.8 MHz)
.delta.: 11.12 (CH.sub.2CH.sub.3), 16.72 (Fuc C-6), 23.39, 24.59,
26.54, 26.72, 27.27, 29.47, 31.86, 33.14, 34.20, 35.06, 42.76 (11C,
EtCy, CH.sub.2Cy), 45.96 (C-3), 62.68 (Gal C-6), 67.77 (Fuc C-5),
67.83 (Gal C-4), 70.30 (Fuc C-2), 71.38 (Fuc C-3), 73.12 (Gal C-2),
73.92 (Fuc C-4), 75.90 (Gal C-5), 77.94 (Lac C-2), 80.77 (C-1),
81.11 (C-2), 83.55 (Gal C-3), 100.20 (Fuc C-1), 100.52 (Gal C-1),
129.67, 130.84, 131.63, 134.37 (6C, C.sub.6H.sub.5), 166.79
(C.dbd.O), 178.76 (CO.sub.2H); HR-MS (ESI) m/z: calcd for
C.sub.36H.sub.54NaO.sub.14[M+Na].sup.+: 733.3406; found: 733.3409
(0.4 ppm).
Example 4
{(1R,2R,3R)-3-cyclopropyl-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-cycl-
ohex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-gal-
actopyranoside (B-IV; FIG. 4)
(1R,2R,3R)-3-Cyclopropyl-1-O-triphenylmethyl-cyclohexane-1,2-diol
(B-I)
[0202] A cPrLi solution was generated in situ by treating a
solution of bromocyclopropane (370 .mu.L, 4.63 mmol) in THF (4 mL)
with tBuLi (1.7 M in pentane, 5.45 mL, 9.27 mmol) during 80 min at
-78.degree. C. CuCN (210 mg, 2.34 mmol) in THF (5 mL) was treated
with the cPrLi solution and BF.sub.3 etherate (115 .mu.L, 0.914
mmol) in THF (1 mL) according to general procedure A. Epoxide A-I
(165 mg, 0.463 mmol) in THF (5 mL) was slowly added and the
reaction slowly warmed to -30.degree. C. (-78.degree. C.: 1.5 h;
-78.degree. C. to -50.degree. C.: 1.5 h; -50.degree.: 24 h;
-50.degree. C. to -30.degree. C.: 40 min). Work-up and purification
according to general procedure A yielded B-I (150.7 mg, 82%).
[0203] [.alpha.].sub.D.sup.21=-38.8 (c=0.50, CH.sub.2Cl.sub.2);
.sup.1H-NMR (CD.sub.2Cl.sub.2, 500.1 MHz) .delta.: -0.16 (m, 1H,
cPr), 0.13-0.23 (m, 2H, cPr), 0.34-0.43 (m, 2H, cPr, H-3),
0.54-0.67 (m, 2H, cPr, H-5.sub.a), 0.91 (m, 1H, H-4.sub.a), 1.18
(m, 1H, H-6.sub.a), 1.27-1.35 (m, 2H, H-5.sub.b, H-6.sub.b), 1.44
(m 1H, H-4.sub.b), 2.52 (s, 1H, OH), 2.71 (ddd, .sup.3J=4.1, 8.6,
11.0 Hz, 1H, H-1), 3.47 (t, .sup.3J=9.1 Hz, 1H, H-2), 7.15-7.23,
7.42-7.43 (2 m, 15H, 3 C.sub.6H.sub.5); .sup.13C-NMR
(CD.sub.2Cl.sub.2, 125.8 MHz) .delta.: 0.85, 4.26, 14.56 (3C, cPr),
23.11 (C-5), 29.50 (C-4), 32.15 (C-6), 46.68 (C-3), 78.55 (C-2),
78.92 (C-1), 86.37 (OCPh.sub.3), 127.07, 127.73, 128.82, 145.37
(18C, 3 C.sub.6H.sub.5); IR (KBr) v: 3571 (m, OH), 3058 (w), 2930
(m), 2858 (m), 1596 (vw), 1490 (m), 1448 (s), 1284 (w), 1225 (w),
1152 (w), 1063 (vs), 926 (w), 844 (vw), 824 (vw), 761 (m), 746 (m),
707 (vs) cm.sup.-1; elemental analysis calcd (%) for
C.sub.28H.sub.30O.sub.2 (398.54): C, 84.38, H, 7.59; found: C,
84.16, H, 7.78.
[(1R,2R,3R)-3-Cyclopropyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-de-
oxy-.alpha.-L-galactopyranoside (B-II)
[0204] According to general procedure B, A-III (223 mg, 0.466 mmol)
in CH.sub.2Cl.sub.2 (1.5 mL) was treated with a solution of
Br.sub.2 (27.5 .mu.L, 0.535 mmol) in CH.sub.2Cl.sub.2 (1 mL) for 30
min at 0.degree. C. After destroying the excess of bromine, the
fucosyl bromide solution was added to a solution of B-I (142 mg,
0.356 mmol) and Et.sub.4NBr (98.9 mg, 0.471 mmol) in
DMF/CH.sub.2Cl.sub.2 (6 mL, 1:1), which has been stirred with
activated 3 .ANG. molecular sieves (1 g) for 4 h. The reaction was
stirred for 67 h at r.t. and then quenched with pyridine (1 mL).
Work-up and purification according to general procedure B yielded
the tritylether (237 mg). To a stirred solution of the tritylether
in CH.sub.2Cl.sub.2 (4 mL), ZnBr.sub.2 (193 mg, 0.859 mmol) and
triethylsilane (70 .mu.L, 0.441 mmol) were added. The reaction was
quenched after 1.75 h by adding H.sub.2O (100 .mu.L). Work-up and
purification according to general procedure B yielded B-II (136 mg,
67% over two steps) as a colorless solid.
[0205] [.alpha.].sub.D.sup.21=-29.0 (c=0.65, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: -0.06 (m, 1H, cPr),
0.08 (m, 1H, cPr), 0.22 (m, 1H, cPr), 0.33 (m, 1H, cPr), 0.87 (m,
1H, H-4.sub.a), 0.96 (m, 1H, cPr), 1.05-1.27 (m, 6H, Fuc H-6, H-3,
H-5.sub.a, H-6.sub.a), 1.54 (m, 1H, H-4.sub.b), 1.64 (m, 1H,
H-5.sub.b), 1.96 (m, 1H, H-6.sub.b), 3.11 (t, .sup.3J=9.1 Hz, 1 H,
H-2), 3.35 (m, 1H, H-1), 3.69 (m, 1H, Fuc H-4), 3.98 (dd,
.sup.3J.sub.F3,F4=2.5 Hz, .sup.3J.sub.F2,F3=10.1 Hz, 1H, Fuc H-3),
4.11-4.16 (m, 2H, Fuc H-2, Fuc H-5), 4.66-4.68 (m, 2H, CH.sub.2Ph),
4.76, 4.77, 4.90, 5.01 (4 m, 4H, CH.sub.2Ph), 5.14 (d,
.sup.3J.sub.F1,F2=3.4 Hz, 1H, Fuc H-1), 7.26-7.41 (m, 15H, 3
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
0.76, 4.93, 13.58 (3C, cPr), 16.56 (Fuc C-6), 22.86 (C-5), 28.32
(C-4), 32.56 (C-6), 44.14 (C-3), 67.64 (Fuc C-5), 73.14, 73.19 (2
CH.sub.2Ph), 73.95 (C-1), 74.85 (CH.sub.2Ph), 76.74 (Fuc C-2),
77.68 (Fuc C-4), 78.63 (Fuc C-3), 92.33 (C-2), 99.20 (Fuc C-1),
127.42, 127.45, 127.50, 127.64, 128.18, 128.22, 128.35, 128.44,
138.44, 138.58, 138.90 (18C, 3 C.sub.6H.sub.5); IR (KBr) v: 3426
(s, OH), 3031 (vw), 3004 (vw), 2933 (s), 1497 (vw), 1453 (m), 1348
(w), 1247 (vw), 1212 (vw), 1161 (m), 1136 (s), 1103 (vs), 1064
(vs), 1026 (vs), 957 (w), 911 (vw), 843 (vw), 736 (s), 696 (s)
cm.sup.-1; elemental analysis calcd (%) for C.sub.36H.sub.44O.sub.6
(572.73): C, 75.50, H, 7.74; found: C, 75.38, H, 7.75.
{(1R,2R,3R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyranosyl)oxy-
]-3-cyclopropyl-cyclohex-1-yl}2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycar-
bonyl-2-cyclohexyl-ethyl]-.beta.-D-galactopyranoside (B-III)
[0206] According to general procedure C, thioglycoside A-Vl (228
mg, 0.292 mmol) and glycosyl acceptor B-II (129 mg, 0.225 mmol) in
dry CH.sub.2Cl.sub.2 (8 mL) were added via syringe to activated 3
.ANG. molecular sieves (2 g). A suspension of DMTST (177 mg, 0.685
mmol) and activated 3 .ANG. molecular sieves (1 g) in
CH.sub.2Cl.sub.2 (4 mL) was prepared in a second flask. Both
suspensions were stirred at r.t. for 4 h, then the DMTST suspension
was added via syringe to the other suspension with some additional
CH.sub.2Cl.sub.2 (2 mL). The reaction was stopped after 48 h and
work-up and purification according to general procedure C afforded
B-III (253 mg, 87%) as a colorless foam.
[0207] [.alpha.].sub.D.sup.21=-43.1 (c=0.61, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: -0.11 (m, 1H, cPr),
0.16 (m, 1H, cPr), 0.32-0.35 (m, 2H, cPr), 0.46-0.53 (m, 2H,
CyCH.sub.2), 0.64-1.46 (m, 18H, CyCH.sub.2, Cy, cPr), 1.38 (d,
.sup.3J.sub.F5,F6=6.4 Hz, 3H, Fuc H-6), 1.80 (m, 1H, H-6.sub.b),
3.52 (t, .sup.3J=7.3 Hz, 1H, H-2), 3.57 (s, 1H, Fuc H-4), 3.62 (m,
1H, H-1), 3.84 (dd, .sup.3J.sub.G3,G4=2.8 Hz, .sup.3J.sub.G2,G3=9.8
Hz, 1H, Gal H-3), 3.93 (m, 1H, Gal H-5), 4.03 (dd,
.sup.3J.sub.F1,F2=3.2 Hz, .sup.3J.sub.F2,F3=10.2 Hz, 1H, Fuc H-2),
4.07 (dd, .sup.3J.sub.F3,F4=1.7 Hz, .sup.3J.sub.F2,F3=10.4 Hz, 1H,
Fuc H-3), 4.13 (dd, .sup.3J=4.5, 7.8 Hz, 1 H, Lac H-2), 4.32-4.40
(m, 3H, Gal H-6, CH.sub.2Ph), 4.53 (m, 1H, CH.sub.2Ph), 4.58 (d,
.sup.3J.sub.G1,G2=8.1 Hz, 1H, Gal H-1), 4.62, 4.68 (2 m, 2H,
CH.sub.2Ph), 4.74-4.76 (m, 2H, Fuc H-5, CH.sub.2Ph), 4.78 (m, 1H,
CH.sub.2Ph), 5.05, 5.11 (2 m, 2H, CH.sub.2Ph), 5.35 (d,
.sup.3J.sub.F1,F2=2.8 Hz, 1H, Fuc H-1), 5.61 (m, 1H, Gal H-2), 5.87
(m, 1H, Gal H-4), 7.20-7.36, 7.42-7.44, 7.52-7.59, 8.03-8.14 (4 m,
35H, 7 C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz)
.delta.: 3.06 (cPr), 5.26 (cPr), 13.55 (cPr), 16.81 (Fuc C-6),
20.97, 25.46, 25.72, 26.07, 27.71, 29.44, 32.62, 33.21, 33.40 (9C,
CyCH.sub.2, Cy), 40.46 (Lac C-3), 45.35 (C-3), 62.50 (Gal C-6),
66.34 (Fuc C-5), 66.61 (CH.sub.2Ph), 70.10 (Gal C-4), 71.49 (Gal
C-5), 72.13 (CH.sub.2Ph), 72.32 (Gal C-2), 74.22 (CH.sub.2Ph),
74.87 (CH.sub.2Ph), 76.15 (Fuc C-2), 77.97 (Gal C-3), 78.38 (Lac
C-2), 78.82 (C-2), 79.13 (Fuc C-4), 79.66 (C-1), 79.83 (Fuc C-3),
97.02 (Fuc C-1), 99.60 (Gal C-1), 126.96, 127.05, 127.20, 127.38,
127.78, 128.05, 128.09, 128.37, 128.43, 128.47, 128.53, 129.61,
129.73, 129.89, 129.93, 129.96, 133.03, 133.16, 133.23, 135.44,
138.51, 138.95, 139.21 (42C, 7 C.sub.6H.sub.5), 164.57, 165.98,
166.16, 172.43 (4 C.dbd.O); IR (KBr) v: 3064 (vw), 3032 (vw), 2927
(s), 2854 (w), 1731 (vs, C.dbd.O), 1602 (vw), 1497 (vw), 1452 (m),
1315 (m), 1267 (vs), 1176 (s), 1097 (vs), 1027 (vs), 840 (vw), 713
(vs) cm.sup.-1; elemental analysis calcd (%) for
C.sub.79H.sub.86O.sub.16 (1291.52): C, 73.47, H, 6.71; found: C,
73.32, H, 6.81.
{(1R,2R,3R)-3-cyclopropyl-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-cycl-
ohex-1-yl}2-O-benzoyl-3-O[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-gala-
ctopyranoside (B-IV; FIG. 4)
[0208] B-III (100 mg, 77.7 .mu.mol) was hydrogenated with
Pd(OH).sub.2/C (52 mg, 10% Pd) in dioxane/H.sub.2O (4:1, 3.75 mL)
according to general procedure D. After 24 h the mixture was
filtered through celite and hydrogenated with fresh Pd(OH).sub.2/C
(50 mg) for another 48 h. The reaction mixture was filtered through
celite and evaporated to dryness. The residue was redissolved in
methanol (5 mL) and sodium methoxide (194 .mu.mol in 190 .mu.l
MeOH) was added. After stirring at r.t. for 16 h the reaction was
quenched by addition of acetic acid (22 .mu.L). The mixture was
concentrated in vacuo and purified by preparative, reversed-phase
HPLC to afford B-IV (40.5 mg, 72%) as a colorless solid.
[0209] [.alpha.].sub.D.sup.21=-85.4 (c=0.75, MeOH); .sup.1H-NMR
(MeOD, 500.1 MHz) .delta.: -0.04 (m, 1H, cPr), 0.33 (m, 1H, cPr),
0.45-0.52 (m, 2H, cPr), 0.56-1.65 (m, 20 H, CyCH.sub.2, cPrCy),
1.30 (d, .sup.3J.sub.F5,F6=6.6 Hz, 3H, Fuc H-6), 1.94 (m, 1H,
H-6.sub.b), 3.45 (t, .sup.3J=8.5 Hz, 1H, H-2), 3.56 (m, 1H, Gal
H-5), 3.62 (m, 1H, H-1), 3.66 (dd, .sup.3J.sub.G3,G4=3.1 Hz,
.sup.3J.sub.G2,G3=9.8 Hz, 1H, Gal H-3), 3.71-3.74 (m, 2H, Gal
H-6.sub.a, Fuc H-2), 3.78 (m, 1H, Fuc H-4), 3.83 (dd,
.sup.3J.sub.G5,G6b=7.1 Hz, .sup.2J.sub.G6a,G6b=11.4 Hz, 1H, Gal
H-6.sub.b), 3.95 (dd, .sup.3J.sub.F3,F4=3.3 Hz,
.sup.3J.sub.F2,F3=10.2 Hz, 1H, Fuc H-3), 3.97 (m, 1H, Gal H-4),
4.06 (dd, .sup.3J=2.9, 9.8 Hz, 1H, Lac H-2), 4.66 (d,
.sup.3J.sub.G1,G2=8.0 Hz, 1H, Gal H-1), 4.88 (m, 1H, Fuc H-5), 5.37
(d, .sup.3J.sub.F1,F2=3.9 Hz, 1H, Fuc H-1), 5.39 (dd,
.sup.3J.sub.G1,G2=8.1 Hz, .sup.3J.sub.G2,G3=9.6 Hz, 1H, Gal H-2),
7.49-7.52, 7.61-7.65, 8.07-8.09 (3 m, 5H, C.sub.6H.sub.5);
.sup.13C-NMR (MeOD, 125.8 MHz) .delta.: 3.96, 7.18, 15.53 (3C,
cPr), 16.72 (Fuc C-6), 22.94, 26.54, 26.73, 27.27, 30.78, 31.45
(6C, CyCH.sub.2, Cy), 33.13, 34.20, 35.07, 42.76 (4C, CyCH.sub.2),
48.49 (C-3), 62.72 (Gal C-6), 67.61 (Fuc C-5), 67.88 (Gal C-4),
70.24 (Fuc C-2), 71.34 (Fuc C-3), 73.16 (Gal C-2), 73.97 (Fuc C-4),
76.02 (Gal C-5), 78.01 (Lac C-2), 80.29 (C-1), 80.52 (C-2), 83.45
(Gal C-3), 98.97 (Fuc C-1), 100.41 (Gal C-1), 129.66, 130.82,
131.63, 134.36 (6C, C.sub.6H.sub.5), 166.76 (C.dbd.O), 178.83
(CO.sub.2H); HR-MS (ESI) m/z: calcd for
C.sub.37H.sub.54NaO.sub.14[M+Na].sup.+: 745.3406; found: 745.3407
(0.1 ppm).
Example 5
{(1R,2R,3S)-3-butyl-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-cyclohex-1-
-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-galactopy-
ranoside sodium salt (C-IV; FIG. 5)
(1R,2R,3S)-3-Butyl-1-O-triphenylmethyl-cyclohexane-1,2-diol
(C-I)
[0210] CuCN (342 mg, 3.81 mmol) in THF (10 mL) was treated with
nBuLi (2.5 M in hexane, 3.05 mL, 7.63 mmol) and BF.sub.3 etherate
(192 .mu.L, 1.53 mmol) in THF (2 mL) according to general procedure
A. Epoxide A-I (271 mg, 0.761 mmol) in THF (8 mL) was slowly added
and the reaction slowly warmed to -30.degree. C. (-78.degree. C.: 1
h; -78.degree. C. to -50.degree. C.: 4 h; -50.degree.: 24 h;
-50.degree. C. to -30.degree. C.: 21 h). Work-up and purification
according to general procedure A yielded C-I (220 mg, 70%).
[0211] [.alpha.].sub.D.sup.21=-37.8 (c=0.66, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.73 (m, 1H,
H-5.sub.a), 0.85 (m, 1H, H-4.sub.a), 0.86 (t, .sup.3J=7.2 Hz, 3H,
H-10), 1.03-1.16 (m, 3 H, H-3, H-7.sub.a, H-8.sub.a), 1.21-1.35 (m,
4H, H-6.sub.a, H-8.sub.b, H-9.sub.a, H-9.sub.b), 1.38-1.49 (m, 2H,
H-5.sub.b, H-6.sub.b), 1.61 (m, 1H, H-4.sub.b), 1.75 (m, 1H,
H-7.sub.b), 2.70 (s, 1H, OH), 2.82 (ddd, .sup.3J=4.0, 8.6, 11.2 Hz,
1H, H-1), 3.40 (t, .sup.3J=9.0 Hz, 1H, H-2), 7.21-7.30, 7.48-7.50
(2 m, 15H, 3 C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz)
.delta.: 14.11 (C-10), 23.10 (C-9), 23.37 (C-5), 28.73 (C-8), 29.38
(C-4), 32.05 (C-7), 32.30 (C-6), 42.45 (C-3), 77.62 (C-2), 79.05
(C-1), 86.43 (CPh.sub.3), 127.05, 127.74, 128.70, 145.12 (18C, 3
C.sub.6H.sub.5); elemental analysis calcd (%) for
O.sub.29H.sub.34O.sub.2 (414.58): C, 84.02, H, 8.27; found: C,
84.05, H, 8.27.
[(1R,2R,3S)-3-Butyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-.a-
lpha.-L-galactopyranoside (C-II)
[0212] According to general procedure B, A-III (308 mg, 0.644 mmol)
in CH.sub.2Cl.sub.2 (3 mL) was treated with a solution of Br.sub.2
(38 .mu.L, 0.740 mmol) in CH.sub.2Cl.sub.2 (1 mL) for 30 min at
0.degree. C. After destroying the excess of bromine, the fucosyl
bromide solution was added to a solution of C-I (205 mg, 0.495
mmol) and Et.sub.4NBr (137 mg, 0.650 mmol) in DMF/CH.sub.2Cl.sub.2
(10 mL, 1:1), which has been stirred with activated 3 .ANG.
molecular sieves (700 mg) for 3.5 h. The reaction was stirred for
67 h at r.t. and then quenched with pyridine (1 mL). Work-up and
purification according to the general procedure B yielded the
tritylether (283 mg) as a yellowish resin. To a stirred solution of
the tritylether in CH.sub.2Cl.sub.2 (4 mL), ZnBr.sub.2 (229 mg,
1.02 mmol) and triethylsilane (81 .mu.L, 0.510 mmol) were added.
The reaction was quenched after 1.25 h by adding H.sub.2O (100
.mu.L). Work-up and purification according to general procedure B
yielded C-II (161 mg, 55% over two steps) as a colorless solid.
[0213] [.alpha.].sub.D.sup.21=-21.3 (c=0.56, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.82 (t, .sup.3J=7.0
Hz, 3H, H-10), 0.86 (m, 1H, H-4.sub.a), 0.98 (m, 1H, H-7.sub.a),
1.15 (d, .sup.3J.sub.F5,F6=6.5 Hz, 3H, Fuc H-6), 1.09-1.37 (m, 7H,
H-3, H-5.sub.a, H-6.sub.a, H-8.sub.a, H-8.sub.b, H-9.sub.a,
H-9.sub.b), 1.66 (m, 1H, H-5.sub.b), 1.81 (m, 1H, H-4.sub.b), 1.98
(m, 1H, H-6.sub.b), 2.10 (m, 1H, H-7.sub.b), 2.94 (t, .sup.3J=9.3
Hz, 1H, H-2), 3.36 (m, 1H, H-1), 3.68 (m, 1H, Fuc H-4), 3.98 (dd,
.sup.3J.sub.F3,F4=2.6 Hz, .sup.3J.sub.F2,F3=10.2 Hz, 1H, Fuc H-3),
4.09-4.14 (m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.70, 4.75, 4.78, 4.85
(5 m, 5H, 3 CH.sub.2Ph), 4.98-5.00 (m, 2H, Fuc H-1, 1 CH.sub.2Ph),
7.25-7.39 (m, 15H, 3 C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3,
125.8 MHz) .delta.: 14.11 (C-10), 16.57 (Fuc C-6), 22.72 (C-9),
23.19 (C-5), 29.03 (C-8), 30.26 (C-4), 31.24 (C-7), 32.55 (C-6),
41.18 (C-3), 67.54 (Fuc C-5), 72.97 (CH.sub.2Ph), 73.26 (C-1),
73.39 (CH.sub.2Ph), 74.84 (CH.sub.2Ph), 76.38 (Fuc C-2), 77.60 (Fuc
C-4), 78.80 (Fuc C-3), 91.47 (C-2), 98.31 (Fuc C-1), 127.40,
127.45, 127.52, 127.61, 127.86, 128.20, 128.21, 128.33, 128.38,
138.32, 138.44, 138.79 (18C, 3 C.sub.6H.sub.5); elemental analysis
calcd (%) for C.sub.37H.sub.48O.sub.6 (588.77): C, 75.48, H, 8.22;
found: C, 75.55, H, 8.28.
{(1R,2R,3S)-2-(2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyranosyl)oxyl-
-3-butyl-cyclohex-1-yl}2,4,6-tri-O-benzoyl-3-O[(1S)-1-benzyloxycarbonyl-2--
cyclohexyl-ethyl]-.beta.-D-galactopyranoside (C-III)
[0214] According to general procedure C, thioglycoside A-Vl (218
mg, 0.279 mmol) and glycosyl acceptor C-II (126 mg, 0.215 mmol) in
dry CH.sub.2Cl.sub.2 (8 mL) were added via syringe to activated 3
.ANG. molecular sieves (2 g). A suspension of DMTST (166 mg, 0.644
mmol) and activated 3 .ANG. molecular sieves (1 g) in
CH.sub.2Cl.sub.2 (4 mL) was prepared in a second flask. Both
suspensions were stirred at r.t. for 4.5 h, then the DMTST
suspension was added via syringe to the other suspension with some
additional CH.sub.2Cl.sub.2 (2 mL). The reaction was stopped after
65.5 h and work-up and purification according to general procedure
C afforded C-III (224 mg, 80%) as a colorless foam.
[0215] [.alpha.].sub.D.sup.21=-46.7 (c=0.49, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.45-1.84 (m, 26H,
CyCH.sub.2, nBuCy), 0.80 (d, .sup.3J=6.8 Hz, 3H, nBu), 1.40 (d,
.sup.3J=6.5 Hz, 3H, Fuc H-6), 3.36 (t, .sup.3J=8.5 Hz, 1H, H-2),
3.52 (s, 1H, Fuc H-4), 3.54 (m, 1 H, H-1), 3.83 (dd,
.sup.3J.sub.G3,G4=3.0 Hz, .sup.3J.sub.G2,G3=9.8 Hz, 1H, Gal H-3),
3.92 (m, 1H, Gal H-5), 4.01 (dd, .sup.3J.sub.F1,F2=3.2 Hz,
.sup.3J.sub.F2,F3=10.3 Hz, 1H, Fuc H-2), 4.04 (dd,
.sup.3J.sub.F3,F4=2.0 HZ, .sup.3J.sub.F2,F3=10.4 Hz, 1H, Fuc H-3),
4.13 (dd, .sup.3J=4.6, 7.8 Hz, 1H, Lac H-2), 4.28 (dd,
.sup.3J.sub.G5,G6a=6.7 Hz, .sup.2J.sub.G6a,G6b=11.4 Hz, 1H, Gal
H-6.sub.a), 4.28 (m, 1H, CH.sub.2Ph), 4.39 (dd,
.sup.3J.sub.G5,G6b=5.8 Hz, .sup.2J.sub.G6a,G6b=11.4 Hz, 1H, Gal
H-6.sub.b), 4.52 (m, 1H, CH.sub.2Ph), 4.56 (d,
.sup.3J.sub.G1,G2=8.1 Hz, 1H, Gal H-1), 4.65, 4.68, 4.74, 4.76 (4
m, 4 H, CH.sub.2Ph), 4.79 (m, 1H, Fuc H-5), 5.01 (d,
.sup.3J.sub.F1,F2=3.0 Hz, 1H, Fuc H-1), 5.05, 5.11 (2 m, 2H,
CH.sub.2Ph), 5.61 (m, 1H, Gal H-2), 5.85 (m, 1H, Gal H-4),
7.20-7.36, 7.42-7.46, 7.52-7.59, 8.04-8.13 (4 m, 35H, 7
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
14.26 (CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 16.81 (Fuc C-6), 21.84,
22.95, 25.46, 25.71, 26.07, 28.34, 28.55, 30.20, 30.39, 32.61,
33.19, 33.39, 40.48, 42.80 (14C, CyCH.sub.2, nBuCy), 62.52 (Gal
C-6), 66.37 (Fuc C-5), 66.63 (CH.sub.2Ph), 70.15 (Gal C-4), 71.45
(Gal C-5), 72.11 (CH.sub.2Ph), 72.21 (Gal C-2), 73.89, 74.92 (2
CH.sub.2Ph), 76.17 (Fuc C-2), 78.05 (Gal C-3), 78.38 (Lac C-2),
78.76 (C-2), 79.23 (Fuc C-4), 79.75 (Fuc C-3), 80.79 (C-1), 97.71
(Fuc C-1), 100.03 (Gal C-1), 126.95, 127.04, 127.21, 127.30,
127.80, 128.04, 128.09, 128.15, 128.39, 128.44, 128.48, 128.49,
128.54, 129.66, 129.71, 129.75, 129.92, 129.94, 133.03, 133.16,
133.25, 135.42, 138.70, 138.99, 139.16 (42C, 7 C.sub.6H.sub.5),
164.56, 166.09, 166.21, 172.47 (4 C.dbd.O); elemental analysis
calcd (%) for C.sub.80H.sub.90O.sub.16 (1307.58): C, 73.49, H,
6.94; found: C, 73.16, H 6.93.
{(1R,2R,3S)-3-butyl-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-cyclohex-1-
-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-galactopy-
ranoside sodium salt (C-IV; FIG. 5).
[0216] C-III (100 mg, 76.5 .mu.mol) was hydrogenated with
Pd(OH).sub.2/C (50 mg, 10% Pd) in dioxane/H.sub.2O (4:1, 3.75 mL)
according to general procedure D. After 19 h the mixture was
filtered through celite and hydrogenated with fresh Pd(OH).sub.2/C
(50 mg) for another 30 h. The reaction mixture was filtered through
celite and evaporated to dryness. The residue was redissolved in
methanol (5 mL) and sodium methoxide (0.191 mmol) was added. After
stirring at r.t. for 17 h the reaction was quenched by addition of
acetic acid (22 .mu.L). The mixture was concentrated in vacuo and
purified by column chromatography (CH.sub.2Cl.sub.2/methanol/water,
3.4:1:0.1 to 2:1:0.1), followed by Dowex 50 (Na.sup.+ form) ion
exchange column, Sephadex G15 column, microfiltration and
lyophilization from dioxane to give C-IV (32.3 mg, 56%) as a
colorless foam. For biological testing a small amount was purified
by preparative, reversed-phase HPLC to afford the free acid of C-IV
as colorless needles.
[0217] C-IV sodium salt: [.alpha.].sub.D.sup.21=-77.9 (c=0.61,
MeOH); .sup.1H-NMR (MeOD, .delta.00.1 MHz) .delta.: 0.47-1.89 (m,
25H, CyCH.sub.2, nBu, Cy), 0.88 (t, .sup.3J=7.1 Hz, 3H, nBu), 1.31
(d, .sup.3J=6.5 Hz, 3H, Fuc H-6), 2.00 (m, 1H, H-6.sub.b), 3.24 (t,
.sup.3J=8.9 Hz, 1H, H-2), 3.56-3.60 (m, 2H, Gal H-5, Gal H-3), 3.65
(m, 1H, H-1), 3.72-3.77 (m, 4 H, Gal H-6.sub.a, Fuc H-2, Fuc H-4,
Lac H-2), 3.80 (dd, .sup.3J.sub.G5,G6b=6.9 Hz,
.sup.2J.sub.G6a,G6b=11.5 Hz, 1H, Gal H-6.sub.b), 3.88 (dd,
.sup.3J.sub.F3,F4=3.3 Hz, .sup.3J.sub.F2,F3=10.3 Hz, 1H, Fuc H-3),
3.95 (m, 1H, Gal H-4), 4.68 (d, .sup.3J.sub.G1,G2=8.1 Hz, 1H, Gal
H-1), 4.85 (m, 1H, Fuc H-5), 4.94 (d, .sup.3J.sub.F1,F2=4.0 Hz, 1H,
Fuc H-1), 5.41 (dd, .sup.3J.sub.G1,G2=8.5 Hz, .sup.3J.sub.G2,G3=9.2
Hz, 1H, Gal H-2), 7.48-7.51, 7.60-7.63, 8.07-8.09 (3 m, 5H,
C.sub.6H.sub.5); .sup.13C-NMR (MeOD, 125.8 MHz) .delta.: 14.48
(nBu), 16.72 (Fuc C-6), 23.27, 23.92, 26.57, 26.82, 27.41, 29.83,
30.04, 31.69, 31.86, 33.06, 34.44, 35.41, 43.54, 44.30 (14C, nBu,
Cy, CH.sub.2Cy), 63.06 (Gal C-6), 67.70 (Gal C-4), 67.84 (Fuc C-5),
70.21 (Fuc C-2), 71.34 (Fuc C-3), 73.08 (Gal C-2), 73.90 (Fuc C-4),
75.92 (Gal C-5), 80.69 (Lac C-2), 80.41 (C-1), 81.37 (C-2), 83.69
(Gal C-3), 99.91 (Fuc C-1), 100.53 (Gal C-1), 129.60, 130.84,
131.76, 134.23 (6C, C.sub.6H.sub.5), 166.87 (C.dbd.O), 183.26
(COON); HR-MS (ESI) m/z: calcd for
C.sub.38H.sub.58NaO.sub.14[M+H].sup.+: 761.3719; found: 761.3710
(1.2 ppm).
[0218] C-IV free acid: .sup.1H-NMR (MeOD, .delta.00.1 MHz) .delta.:
0.54-1.91 (m, 25H, CyCH.sub.2, nBu, Cy), 0.89 (t, .sup.3J=7.1 Hz,
3H, nBu), 1.32 (d, .sup.3J=6.6 Hz, 3H, Fuc H-6), 1.98 (m, 1H,
H-6.sub.b), 3.23 (t, .sup.3J=8.9 Hz, 1H, H-2), 3.56 (m, 1H, Gal
H-5), 3.62 (m, 1H, H-1), 3.66 (dd, .sup.3J.sub.G3,G4=3.0 Hz,
.sup.3J.sub.G2,G3=9.8 Hz, 1H, Gal H-3), 3.70-3.75 (m, 3H, Gal
H-6.sub.a, Fuc H-2, Fuc H-4), 3.79 (dd, .sup.3J.sub.G6b,G5=6.9 Hz,
.sup.2J.sub.G6a,G6b=11.3 Hz, 1H, Gal H-6.sub.b), 3.85 (dd,
.sup.3J.sub.F3,F4=3.3 Hz, .sup.3J.sub.F2,F3=10.3 Hz, 1H, Fuc H-3),
3.97 (m, 1H, Gal H-4), 4.06 (dd, .sup.3J=2.9, 9.9 Hz, 1H, Lac H-2),
4.67 (d, .sup.3J.sub.G1,G2=8.1 Hz, 1H, Gal H-1), 4.88-4.92 (m, 2H,
Fuc H-1, Fuc H-5), 5.43 (dd, .sup.3J.sub.G1,G2=8.2 Hz,
.sup.3J.sub.G2,G3=9.6 Hz, 1H, Gal H-2), 7.49-7.52, 7.62-7.64,
8.07-8.09 (3 m, 5H, C.sub.6H.sub.5); .sup.13C-NMR (MeOD, 125.8 MHz)
.delta.: 14.48 (nBu), 16.74 (Fuc C-6), 23.38, 23.90, 26.54, 26.72,
27.28, 29.83, 29.99, 31.71, 31.81, 33.12, 34.19, 35.07, 42.78,
44.51 (14C, nBu, Cy, CH.sub.2Cy), 62.69 (Gal C-6), 67.79 (2C, Fuc
C-5, Gal C-4), 70.27 (Fuc C-2), 71.43 (Fuc C-3), 73.10 (Gal C-2),
73.94 (Fuc C-4), 75.90 (Gal C-5), 77.93 (Lac C-2), 80.71 (C-1),
81.45 (C-2), 83.57 (Gal C-3), 100.29 (Fuc C-1), 100.52 (Gal C-1),
129.67, 130.85, 131.63, 134.37 (6C, C.sub.6H.sub.5), 166.77
(C.dbd.O), 178.84 (CO.sub.2H).
Example 6
{(1R,2R,3R)-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-3-(2-methoxycarbon-
yl-ethyl)-cyclohex-1-yl}2-O-BENZOYL-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl-
]-.beta.-D-galactopyranoside (D-III; FIG. 6)
[(1R,2R,3R)-1-Hydroxy-3-(2-methoxycarbonyl-ethyl)-cyclohex-2-yl]2,3,4-tris-
-.beta.-benzyl-6-deoxy-.alpha.-L-galactopyranoside (D-I)
[0219] A-IV (106 mg, 0.189 mmol) was dissolved in CH.sub.2Cl.sub.2
(5 mL) and Grubbs cat. 2.sup.nd gen. (16.0 mg 18.8 .mu.mol) and
methyl acrylate (171 .mu.L, 1.90 mmol) were added. The reaction was
heated under reflux for 9 d. After 1 d, 2 d and 7 d additional
Grubbs cat. 2.sup.nd gen. (each 16.0 mg, 18.8 .mu.mol) and methyl
acrylate (each 171 .mu.L, 1.90 mmol) were added. The mixture was
concentrated under reduced pressure and purified by column
chromatography (petroleum ether/ethyl acetate, 5:1 to 4:1) to yield
an E/Z mixture (53.9 mg), which was directly used for
hydrogenation. A solution of the E/Z-mixture in THF (4 mL) was
added to Pd/C (28.0 mg, 10% Pd) under argon. The mixture was
hydrogenated under atmospheric pressure at r.t. After 30 min the
reaction was filtered through celite, concentrated under reduced
pressure and purified by column chromatography (petroleum
ether/ethyl acetate, 3:1 to 2:1) to yield D-I (29.1 mg, 25%) as a
brownish oil.
[0220] [.alpha.].sub.D.sup.21=-21.2 (c=1.46, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.94 (m, 1H), 1.14 (d,
.sup.3J.sub.F6,F5=6.5 Hz, 3H, Fuc H-6), 1.19-1.28 (m, 2H),
1.35-1.47 (m, 2H), 1.67 (m, 1H), 1.74 (m, 1H), 1.99 (m, 1H),
2.29-2.36 (m, 3H), 2.97 (t, .sup.3J=9.2 Hz, 1H, H-2), 3.36 (m, 1H,
H-1), 3.57 (s, 3H, Me), 3.67 (m, 1H, Fuc H-4), 3.98 (dd,
.sup.3J.sub.F3,F4=2.4 Hz, .sup.3J.sub.F2,F3=10.2 Hz, 1H, Fuc H-3),
4.09-4.13 (m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.71, 4.76, 4.78, 4.85
(5 m, 5H, CH.sub.2Ph), 4.96 (d, .sup.3J.sub.F1,F2=3.4 Hz, 1H, Fuc
H-1), 4.99 (1 m, 1H, CH.sub.2Ph), 7.25-7.41 (m, 15H, 3
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
16.50 (Fuc C-6), 23.03, 27.48, 30.37, 32.02, 32.33 (5C), 40.72
(C-3), 51.30 (Me), 67.64 (Fuc C-5), 72.97, 73.00 (CH.sub.2Ph, C-1),
73.48, 74.82 (2 CH.sub.2Ph), 76.01 (Fuc C-2), 77.50 (Fuc C-4),
78.84 (Fuc C-3), 91.25 (C-2), 98.33 (Fuc C-1), 127.43, 127.47,
127.58, 127.62, 127.92, 128.19, 128.28, 128.34, 128.36, 138.23,
138.36, 138.73 (18C, 3 C.sub.6H.sub.5), 174.33 (COOMe); HR-MS (ESI)
m/z: calcd for C.sub.37H.sub.46NaO.sub.8[M+Na].sup.+: 641.3085;
found: 641.3080 (0.8 Ppm).
{(1R,2R,3R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyranosyl)oxy-
]-3-(2-methoxycarbonyl-ethyl)-cyclohex-1-yl}2,4,6-tri-O-benzoyl-3-O-[(1S)--
1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-.beta.-D-galactopyranoside
(D-II)
[0221] According to general procedure C, thioglycoside A-VI (47.9
mg, 61.3 .mu.mol) and glycosyl acceptor D-I (29.1 mg, 47.0 .mu.mol)
in dry CH.sub.2Cl.sub.2 (4 mL) were added via syringe to activated
3 .ANG. molecular sieves (500 mg). A suspension of DMTST (37.6 mg,
146 .mu.mol) and activated 3 .ANG. molecular sieves (250 mg) in
CH.sub.2Cl.sub.2 (2 mL) was prepared in a second flask. Both
suspensions were stirred at r.t. for 4 h, then the DMTST suspension
was added via syringe to the other suspension with some additional
CH.sub.2Cl.sub.2 (1 mL). The reaction was stopped after 65.5 h and
work-up according to general procedure C and purification by column
chromatography (petroleum ether/ethyl acetate, 4:1 to 3:1) afforded
D-II (49.5 mg, 79%) as a colorless foam.
[0222] [.alpha.].sub.D.sup.21=-38.1 (c=0.59, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.45-1.57 (m, 19H,
CyCH.sub.2, Cy), 1.37 (d, .sup.3J=6.4 Hz, 3H, Fuc H-6), 1.61 (m,
1H, (CH.sub.2).sub.2CO.sub.2Me), 1.82 (m, 1H, H-6.sub.b), 2.13-2.26
(m, 3H, (CH.sub.2).sub.2CO.sub.2Me), 3.39 (t, .sup.3J=8.1 Hz, 1H,
H-2), 3.51 (s, 1H, Fuc H-4), 3.53-3.56 (m, 4H, H-1, Me), 3.84 (dd,
.sup.3J.sub.G3,G4=3.3 Hz, .sup.3J.sub.G2,G3=9.9 Hz, 1H, Gal H-3),
3.93 (m, 1H, Gal H-5), 3.98-4.03 (m, 2H, Fuc H-2, Fuc H-3), 4.13
(dd, .sup.3J=4.5, 8.0 Hz, 1H, Lac H-2), 4.28 (dd,
.sup.3J.sub.G5,G6a=7.2 Hz, .sup.2J.sub.G6a,G6b=11.4 Hz, 1H, Gal
H-6.sub.a), 4.31 (m, 1H, CH.sub.2Ph), 4.38 (dd,
.sup.3J.sub.G5,G6b=5.6 Hz, .sup.2J.sub.G6a,G6b=11.4 Hz, 1H, Gal
H-6.sub.b), 4.54 (m, 1H, CH.sub.2Ph), 4.55 (d,
.sup.3J.sub.G1,G2=8.0 Hz, 1H, Gal H-1), 4.66-4.71 (m, 3H,
CH.sub.2Ph, Fuc H-5), 4.73, 4.77 (2 m, 2H, CH.sub.2Ph), 5.02 (d,
.sup.3J.sub.F1,F2=2.3 Hz, 1H, Fuc H-1), 5.05, 5.12 (2 m, 2H,
CH.sub.2Ph), 5.60 (m, 1H, Gal H-2), 5.85 (m, 1H, Gal H-4),
7.19-7.34, 7.42-7.47, 7.53-7.59, 8.03-8.13 (4 m, 35H, 7
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
16.78 (Fuc C-6), 21.18, 25.44, 25.66, 25.70, 26.05, 27.84, 31.26,
32.57, 33.19, 33.38, 40.45 (12C, CyCH.sub.2, Cy,
(CH.sub.2).sub.2CO.sub.2Me), 41.94 (0-3), 51.42 (CO.sub.2Me), 62.54
(Gal C-6), 66.50 (Fuc C-5), 66.62 (CH.sub.2Ph), 70.09 (Gal C-4),
71.48 (Gal C-5), 72.24 (2C, CH.sub.2Ph, Gal C-2), 73.79, 74.90 (2
CH.sub.2Ph), 76.26 (Fuc C-2), 77.91 (Gal C-3), 78.34, 78.38 (Lac
C-2, C-2), 79.09 (Fuc C-4), 79.53 (Fuc C-3), 80.22 (0-1), 97.70
(Fuc C-1) 99.93 (Gal C-1), 126.96, 127.06, 127.23, 127.29, 127.83,
128.04, 128.06, 128.08, 128.15, 128.38, 128.44, 128.48, 128.53,
128.57, 129.62, 129.65, 129.69, 129.74, 129.86, 129.88, 129.94,
129.99, 133.05, 133.19, 133.24, 135.39, 138.64, 138.99, 139.07
(42C, 7 C.sub.6H.sub.5), 164.55, 166.06, 166.17, 172.45, 174.02 (5
C.dbd.O); elemental analysis calcd (%) for C.sub.80H.sub.88O.sub.18
(1337.54): C, 71.84, H, 6.63; found: C, 71.70, H, 6.73.
{(1R,2R,3R)-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-3-(2-methoxycarbon-
yl-ethyl)-cyclohex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl-
]-.beta.-D -galactopyranoside (D-III; FIG. 6).
[0223] D-III (46.0 mg, 34.4 .mu.mol) was hydrogenated with
Pd(OH).sub.2/C (25 mg, 10% Pd) in dioxane/H.sub.2O (4:1, 3.75 mL)
according to general procedure D. After 42 h the mixture was
filtered through celite and hydrogenated with fresh Pd(OH).sub.2/C
(27 mg) for additional 24 h. The reaction mixture was filtered
through celite and evaporated to dryness. The residue was
redissolved in methanol (3 mL) and sodium methoxide (51.6 .mu.mol
in 55 .mu.l MeOH) was added. After stirring at r.t. for 16 h the
reaction was quenched by addition of acetic acid (6 .mu.L). The
mixture was concentrated in vacuo and purified by preparative,
reversed-phase HPLC to afford D-III (19.2 mg, 73%) as a colorless
solid.
[0224] [.alpha.].sub.D.sup.21=-78.3 (c=0.63, MeOH); .sup.1H-NMR
(MeOD, 500.1 MHz) .delta.: 0.55-0.75 (m, 4H, CyCH.sub.2), 0.84-0.96
(m, 2H, CyCH.sub.2, H-4.sub.a), 1.04 (m, 1H, H-6.sub.a), 1.14 (m,
1H, H-5.sub.a), 1.21-1.36 (m, 5H, CyCH.sub.2), 1.32 (d, .sup.3J=6.6
Hz, 3H, Fuc H-6), 1.39-1.60 (m, 6H, CyCH.sub.2, H-3, H-5.sub.b,
(CH.sub.2).sub.2CO.sub.2Me), 1.66 (m, 1H, H-4.sub.b), 1.97 (m, 1H,
H-6.sub.b), 2.18-2.38 (m, 3H, CyCH.sub.2,
(CH.sub.2).sub.2CO.sub.2Me), 3.27 (t, .sup.3J=8.4 Hz, 1H, H-2),
3.57 (m, 1H, Gal H-5), 3.63-3.68 (m, 5H, CH.sub.3, Gal H-3, H-1),
3.71-3.75 (m, 3H, Gal H-6.sub.a, Fuc H-2, Fuc H-4), 3.79 (dd,
.sup.3J.sub.G5,G6b=6.8 Hz, .sup.2J.sub.G6a,G6b=11.3 Hz, 1H, Gal
H-6.sub.b), 3.84 (dd, .sup.3J.sub.F3,F4=3.3 Hz,
.sup.3J.sub.F2,F3=10.2 Hz, 1H, Fuc H-3), 3.98 (m, 1 H, Gal H-4),
4.07 (dd, .sup.3J=3.0, 9.9 Hz, 1H, Lac H-2), 4.67 (d,
.sup.3J.sub.G1,G2=8.1 Hz, 1H, Gal H-1), 4.83 (m, 1H, Fuc H-5), 4.92
(m, 1H, Fuc H-1), 5.43 (dd, .sup.3J.sub.G1,G2=8.2 Hz,
.sup.3J.sub.G2,G3=9.6 Hz, 1H, Gal H-2), 7.49-7.52, 7.62-7.65,
8.08-8.09 (3 m, 5H, C.sub.6H.sub.5); .sup.13C-NMR (MeOD, 125.8 MHz)
.delta.: 16.73 (Fuc C-6), 22.77 (C-5), 26.55, 26.73, 27.28, 27.34
(4C, CyCH.sub.2), 29.49 (C-4), 31.34 (C-6), 32.16
((CH.sub.2).sub.2CO.sub.2Me), 33.13, 34.20, 35.07 (3C, CyCH.sub.2),
42.78 ((CH.sub.2).sub.2CO.sub.2Me), 43.52 (C-3), 52.03 (Me), 62.62
(Gal C-6), 67.81 (Gal C-4), 67.89 (Fuc C-5), 70.25 (Fuc C-2), 71.41
(Fuc C-3), 73.09 (Gal C-2), 73.90 (Fuc C-4), 75.92 (Gal C-5), 77.98
(Lac C-2), 80.36 (C-1), 80.96 (C-2), 83.50 (Gal C-3), 100.34 (Fuc
C-1), 100.50 (Gal C-1), 129.68, 130.85, 131.62, 134.39 (6C,
C.sub.6H.sub.5), 166.77, 176.09, 178.86 (3 C.dbd.O); elemental
analysis calcd (%) for C.sub.38H.sub.56O.sub.16 (768.84)+1 1/2
H.sub.2O: C, 57.35, H, 7.47; found: C, 57.57, H 7.36; HR-MS (ESI)
m/z: calcd for C.sub.38H.sub.56NaO.sub.16[M+Na].sup.+: 791.3461;
found: 791.3463 (0.3 ppm).
Example 7
{(1R,2R,5R)-5-tert-butyl-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-cyclo-
hex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-gala-
ctopyranoside (E-XI; FIG. 7)
rac-(1S,2R,5S)-5-tert-butyl-2-hydroxycyclohexyl benzoate (rac-E-IV)
and rac-(1S,2R,4S)-4-tert-butyl-2-hydroxycyclohexyl benzoate
(rac-E-V)
[0225] 4-tert-Butylcatechol (E-I) (2.02 g, 12.2 mmol),
Rh/Al.sub.2O.sub.3 (98.9 mg), cyclohexane (4 mL) and THF (0.5 mL)
were hydrogenated under 5 bar at r.t. After 24 h the mixture was
filtered through celite and evaporated to dryness. The residue was
purified by MPLC on silica (CH.sub.2Cl.sub.2/ethyl acetate, 3:1 to
1:3) to afford a mixture of syn-diols (1.64 g, 78%,
rac-E-II:rac-E-III, 1.4:1) as a white solid. The mixture (1.64 g,
9.55 mmol) and dibutyltin oxide (2.37 g, 9.52 mmol) were dissolved
in CH.sub.2Cl.sub.2 (50 mL) and cooled to 0.degree. C. Et.sub.3N
(2.68 mL, 19.2 mmol) and benzoyl chloride (1.32 mL, 11.45 mmol)
were slowly added via syringe. The mixture was warmed to r.t.
during 3 h and then quenched with MeOH (2 mL). The solvents were
evaporated in vacuo and the crude residue was purified by MPLC on
silica (toluene/ethyl acetate, 10:0 to 10:1) affording rac-E-IV
(1.15 g, 44%) and rac-E-V (688 mg, 26%) as white solids.
[0226] rac-E-IV: .sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.90
(s, 9H, tBu), 1.23 (m, 1H, H-5), 1.42 (m, 1H, H-4.sub.a), 1.50-1.57
(m, 2H, H-3.sub.a, H-4.sub.b), 1.68 (m, 1H, H-6.sub.a), 1.85 (m,
1H, H-6.sub.b), 2.04 (m, 1H, H-3.sub.b), 4.17 (m, 1H, H-2), 5.05
(ddd, .sup.3J=2.7, 4.7, 11.9 Hz, 1H, H-1), 7.44-7.47, 7.56-7.59,
8.05-8.07 (3 m, 5H, C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3,
125.8 MHz) .delta.: 19.59 (C-4), 26.42 (C-6), 27.51 (3C, tBu),
30.57 (C-3), 32.49 (tBu), 46.35 (C-5), 67.10 (C-2), 76.47 (C-1),
128.39, 129.58, 130.27, 133.07 (6C, C.sub.6H.sub.5), 165.62
(C.dbd.O); HR-MS (ESI) m/z: calcd for
C.sub.17H.sub.24NaO.sub.3[M+Na].sup.+: 299.1618; found: 299.1621
(1.0 ppm).
[0227] rac-E-V: .sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.89
(s, 9H, tBu), 1.18 (m, 1 H, H-5.sub.a), 1.34 (m, 1H, H-3.sub.a),
1.56 (m, 1H, H-4), 1.83-1.98 (m, 3H, H-5.sub.b, H-6), 2.04 (m, 1H,
H-3.sub.b), 4.25 (m, 1H, H-2), 4.98 (ddd, .sup.3J=2.8, 4.9, 11.7
Hz, 1H, H-1), 7.44-7.47, 7.56-7.59, 8.04-8.06 (3 m, 5H,
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
25.07 (C-5), 25.27 (C-6), 27.48 (3C, tBu), 31.91 (tBu), 31.98
(C-3), 39.43 (C-4), 68.14 (C-2), 75.87 (C-1), 128.39, 129.58,
130.28, 133.06 (6C, C.sub.6H.sub.5), 165.72 (C.dbd.O); HR-MS (ESI)
m/z: calcd for C.sub.17H.sub.24NaO.sub.3[M+Na].sup.+: 299.1618;
found: 299.1621 (1.0 ppm).
rac-(1R,2R,4R)-2-(Benzoyloxy)-4-tert-butylcyclohexyl
3,5-dinitrobenzoate (rac-E-VI)
[0228] rac-E-IV (400 mg, 1.45 mmol), triphenylphosphine (1.14 g,
4.33 mmol) and 3,5-dinitrobenzoic acid (921 mg, 4.34 mmol) were
dissolved in toluene (25 mL). Diethyl azodicarboxylate (680 .mu.L,
4.32 mmol) was slowly added to the reaction via syringe. The
mixture was warmed to 50.degree. C. and stirred for 1 d. The
solvent was evaporated in vacuo and the residue, redissolved in a
small amount of CH.sub.2Cl.sub.2, was purified by MPLC on silica
(petroleum ether/ethyl acetate, 10:0 to 10:1) affording rac-E-VI
(428 mg, 63%) and recovered starting material rac-E-IV (103 mg,
26%) as white solids.
[0229] .sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.93 (s, 9H,
tBu), 1.25-1.47 (m, 3H, H-3.sub.a, H-4, H-5.sub.a), 1.68 (m, 1H,
H-6.sub.a), 1.94 (m, 1H, H-5.sub.b), 2.29-2.35 (m, 2H, H-3.sub.b,
H-6.sub.b), 5.27 (ddd, .sup.3J=4.9, 9.7, 11.4 Hz, 1H, H-1), 5.35
(ddd, .sup.3J=4.7, 9.9, 10.5 Hz, 1H, H-2), 7.36-7.39, 7.48-7.52,
7.96-7.98 (3 m, 5H, C.sub.6H.sub.5), 9.06, 9.14-9.15 (2 m, 3H,
C.sub.6H.sub.3); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
24.79 (C-5), 27.52 (3C, tBu), 29.76 (C-6), 31.79 (C-3), 32.36
(tBu), 45.73 (C-4), 74.80 (C-2), 77.55 (C-1), 122.31, 128.39,
129.44, 129.58, 129.74, 133.17, 133.81, 148.54 (12C,
C.sub.6H.sub.5, C.sub.6H.sub.3), 162.16, 165.89 (2 C.dbd.O); HR-MS
(ESI) m/z: calcd for C.sub.24H.sub.26N.sub.2NaO.sub.8[M+Na].sup.+:
493.1581; found: 493.1582 (0.2 ppm).
rac-(1R,2R,5R)-5-tert-Butyl-2-hydroxycyclohexyl benzoate
(rac-E-VII)
[0230] rac-E-VI (135 mg, 0.287 mmol) was suspended in MeOH (5 mL).
Et.sub.3N (1 mL) was added and the reaction stirred for 1 h. The
solvents were evaporated in vacuo and the residue was purified by
MPLC on silica (toluene/ethyl acetate, 6:0 to 6:1) affording
rac-E-VII (63.2 mg, 80%) as a white solid.
[0231] .sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.88 (s, 9H,
tBu), 1.12 (m, 1H, H-4.sub.a), 1.19-1.32 (m, 2H, H-5, H-6.sub.a),
1.41 (m, 1H, H-3.sub.a), 1.80 (m, 1H, H-4.sub.b), 2.12-2.18 (m, 2H,
H-3.sub.b, H-6.sub.b), 3.69 (ddd, .sup.3J=4.9, 9.3, 11.3 Hz, 1H,
H-2), 4.88 (ddd, .sup.3J=4.7, 9.4, 10.7 Hz, 1H, H-1), 7.43-7.46,
7.55-7.58, 8.06-8.07 (3 m, 5H, C.sub.6H.sub.5); .sup.13C-NMR
(CDCl.sub.3, 125.8 MHz) .delta.: 24.89 (C-4), 27.54 (3C, tBu),
31.44 (C-6), 32.28 (tBu), 32.61 (C-3), 46.01 (C-5), 73.33 (C-2),
79.47 (C-1), 128.34, 129.64, 130.23, 133.05 (6C, C.sub.6H.sub.5),
166.82 (C.dbd.O); HR-MS (ESI) m/z: calcd for
C.sub.17H.sub.24NaO.sub.3[M+Na].sup.+: 299.1618; found: 299.1619
(0.3 ppm).
[(1R,2R,5R)-5-tert-Butyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deo-
xy-.alpha.- and .beta.-L-galactopyranoside (E-VIII) and
[(1S,2S,5S)-5-tert-Butyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-de-
oxy-.alpha.-L-galactopyranoside (E-IX)
[0232] A mixture of rac-E-VII (76.9 mg, 0.278 mmol), A-VI (202 mg,
0.421 mmol), Bu.sub.4NBr (274 mg, 0.850 mmol) and powdered 4 .ANG.
molecular sieves (1 g) in CH.sub.2Cl.sub.2 (4 mL) and DMF (1 mL)
was stirred at r.t. under argon for 3.5 h. Then, CuBr.sub.2 (188
mg, 0.844 mmol) was added and the reaction mixture was stirred at
r.t. for 11 h. The reaction mixture was filtered through celite and
the filtrate was diluted with CH.sub.2Cl.sub.2 (30 mL). The organic
layer was successively washed with satd. aqueous NaHCO.sub.3 and
brine (each 30 mL) and the aqueous layers were extracted with
CH.sub.2Cl.sub.2 (3.times.40 mL). The combined organic layers were
dried with Na.sub.2SO.sub.4, filtered and co-evaporated with
toluene to dryness. The residue was purified by MPLC on silica
(petroleum ether/CH.sub.2Cl.sub.2/diethyl ether, 2:1:0 to 2:1:1) to
afford the fucosylated diastereomers. To a stirred solution of
these diastereomers in methanol/water (5:1, 6 mL), lithium
hydroxide (200 mg) was added and the mixture warmed to 50.degree.
C. After stirring for 4 h the reaction mixture was diluted with
CH.sub.2Cl.sub.2 (30 mL) and the organic layer was washed with
brine (50 mL). The aqueous layer was extracted with
CH.sub.2Cl.sub.2 (3.times.30 mL), and the combined organic layers
were dried with Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The residue was purified by MPLC on silica (petroleum
ether/ethyl acetate, 4:0 to 4:1) to yield E-VIII (72.1 mg, 44%,
.alpha.:.beta.=1:0.12, yield over two steps) as an anomeric mixture
and E-IX (63.0 mg, 38%, yield over two steps) as pure
.alpha.-anomer.
[0233] .alpha.-E-VIII: [.alpha.].sub.D.sup.21-41.3 (c=0.31,
CHCl.sub.3); .sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.86 (s,
9H, tBu), 0.97-1.38 (m, 7H, Fuc H-6, H-3.sub.a, H-4.sub.a, H-5,
H-6.sub.a), 1.74 (m, 1 H, H-4.sub.b), 1.99-2.06 (m, 2H, H-3.sub.b,
H-6.sub.b), 3.22 (m, 1H, H-2), 3.47 (m, 1H, H-1), 3.70 (m, 1H, Fuc
H-4), 3.94 (dd, .sup.3J.sub.F3,F4=2.4 Hz, .sup.3J.sub.F2,F3=10.1
Hz, 1H, Fuc H-3), 4.05-4.09 (m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.66,
4.75, 4.82, 4.87 (5 m, 5H, CH.sub.2Ph), 4.97-5.00 (m, 2H, Fuc H-1,
CH.sub.2Ph), 7.26-7.41 (m, 15H, 3 C.sub.6H.sub.5); .sup.13C-NMR
(CDCl.sub.3, 125.8 MHz) .delta.: 16.65 (Fuc C-6), 25.17 (C-4),
27.55 (3C, tBu), 29.54 (C-3), 32.19 (tBu), 33.63 (C-6), 45.82
(C-5), 66.97 (Fuc C-5), 73.15, 73.33 (2 CH.sub.2Ph), 73.52 (C-1),
74.86 (CH.sub.2Ph), 76.16 (Fuc C-2), 77.41 (Fuc C-4), 79.21 (Fuc
C-3), 84.09 (C-2), 96.33 (Fuc C-1), 127.40, 127.48, 127.64, 127.69,
127.90, 128.21, 128.35, 128.44, 138.41, 138.50, 138.81 (18C, 3
C.sub.6H.sub.5); HR-MS (ESI) m/z: calcd for
C.sub.37H.sub.48NaO.sub.6[M+Na].sup.+: 611.3343; found: 611.3346
(0.5 ppm).
[0234] E-IX: [.alpha.].sub.D.sup.21=-40.7 (c=0.38, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.85 (s, 9H, tBu),
1.01-1.17 (m, 6H, Fuc H-6, H-4.sub.a, H-5, H-6.sub.a), 1.29 (m, 1H,
H-3.sub.a), 1.70 (m, 1H, H-4.sub.b), 1.97-2.04 (m, 2H, H-3.sub.b,
H-6.sub.b), 3.17 (m, 1H, H-2), 3.45 (m, 1H, H-1), 3.69 (m, 1H, Fuc
H-4), 3.96-4.05 (m, 3H, Fuc H-2, Fuc H-3, Fuc H-5), 4.66, 4.73,
4.76, 4.81, 4.87, 4.97 (6 m, 6H, CH.sub.2Ph), 4.98 (m, 1H, Fuc
H-1), 7.26-7.41 (m, 15H, 3 C.sub.6H.sub.5); .sup.13C-NMR
(CDCl.sub.3, 125.8 MHz) .delta.: 16.69 (Fuc C-6), 25.32 (C-4),
27.58 (3C, tBu), 31.26 (C-3), 32.25 (tBu), 32.88 (C-6), 45.78
(C-5), 66.57 (Fuc C-5), 72.63, 74.19 (2 CH.sub.2Ph), 74.66 (C-1),
74.80 (CH.sub.2Ph), 76.33 (Fuc C-2), 77.40 (Fuc C-4), 80.01 (Fuc
C-3), 87.22 (C-2), 101.01 (Fuc C-1), 127.34, 127.52, 127.58,
127.84, 128.18, 128.22, 128.34, 128.39, 128.47, 137.95, 138.53,
138.65 (18C, 3 C.sub.6H.sub.5).
[0235]
{(1R,2R,5R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyrano-
syl)oxy]-5-tert-butyl-cyclohex-1-yl}2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyl-
oxycarbonyl-2-cyclohexyl-ethyl]-.beta.-b-galactopyranoside
(E-X).
[0236] According to general procedure C, thioglycoside A-VI (125
mg, 0.161 mmol) and glycosyl acceptor E-VIII (71.4 mg, 0.121 mmol)
in dry CH.sub.2Cl.sub.2 (4 mL) were added via syringe to activated
4 .ANG. molecular sieves (1 g). A suspension of DMTST (120 mg,
0.465 mmol) and activated 4 .ANG. molecular sieves (500 mg) in
CH.sub.2Cl.sub.2 (2 mL) was prepared in a second flask. Both
suspensions were stirred at r.t. for 2 h, before adding the DMTST
suspension via syringe to the other suspension with some additional
CH.sub.2Cl.sub.2 (1 mL). The reaction was stopped after 45 h and
worked-up according to general procedure C. The crude product was
purified by MPLC on silica (toluene/ethyl acetate, 11.5:0 to
11.5:1) to yield E-X (107 mg, 68%) as a colorless foam.
[0237] [.alpha.].sub.D.sup.21=-57.9 (c=0.50, CHCl.sub.3);
.sup.1H-NMR (CDCl.sub.3, 500.1 MHz) .delta.: 0.46-1.43 (3 m, 17H,
CyCH.sub.2, Cy), 0.58 (s, 9H, tBu), 1.36 (d, .sup.3J=6.0 Hz, 3H,
Fuc H-6), 1.60 (m, 1H, H-4.sub.b), 1.81 (m, 1H, H-6.sub.b), 1.99
(m, 1H, H-3.sub.b), 3.45 (m, 1H, H-2), 3.55 (m, 1H, H-1), 3.58 (s,
1H, Fuc H-4), 3.87-3.90 (m, 2H, Gal H-3, Gal H-5), 3.97-4.04 (m,
2H, Fuc H-2, Fuc H-3), 4.16 (m, 1H, Lac H-2), 4.29 (m, 2H, Gal
H-6), 4.39 (m, 1H, CH.sub.2Ph), 4.55-4.57 (m, 2H, Gal H-1,
CH.sub.2Ph), 4.63 (m, 1H, CH.sub.2Ph), 4.69-4.74 (m, 2H,
CH.sub.2Ph), 4.79-4.83 (m, 2H, Fuc H-5, CH.sub.2Ph), 4.88 (d,
.sup.3J.sub.F1,F2=2.1 Hz, 1H, Fuc H-1), 5.04, 5.13 (2 m, 2H,
CH.sub.2Ph), 5.56 (m, 1H, Gal H-2), 5.91 (m, 1H, Gal H-4),
7.17-7.35, 7.39-7.48, 7.54-7.55, 8.04-8.11 (m, 35H, 7
C.sub.6H.sub.5); .sup.13C-NMR (CDCl.sub.3, 125.8 MHz) .delta.:
16.62 (Fuc C-6), 24.43 (C-4), 25.40, 25.71, 26.06 (3C, CyCH.sub.2),
27.19 (3C, tBu), 28.97 (C-3), 31.95 (tBu), 32.23 (C-6), 32.49,
33.17, 33.44 (3C, CyCH.sub.2), 40.44 (CyCH.sub.2), 45.50 (C-5),
62.21 (Gal C-6), 65.98 (Fuc C-5), 66.58 (CH.sub.2Ph), 69.86 (Gal
C-4), 71.19 (Gal C-5), 72.53, 72.56 (Gal C-2, CH.sub.2Ph), 73.02
(CH.sub.2Ph), 74.90 (CH.sub.2Ph), 75.25 (C-2), 76.44 (Fuc C-2),
77.51 (Gal C-3), 78.08 (Lac C-2), 79.24 (Fuc C-4), 79.64 (Fuc C-3),
81.37 (C-1), 94.16 (Fuc C-1), 100.24 (Gal C-1), 126.87, 126.95,
127.22, 127.38, 127.93, 127.95, 128.03, 128.15, 128.34, 128.42,
128.47, 128.50, 129.64, 129.74, 129.83, 129.88, 129.91, 133.04,
133.16, 133.21, 135.43, 138.86, 139.08, 139.14 (42C, 7
C.sub.6H.sub.5), 164.56, 165.65, 166.11, 172.47 (4 C.dbd.O);
elemental analysis calcd (%) for C.sub.80H.sub.90O.sub.16
(1307.56): C, 73.48, H, 6.94; found: C, 73.50, H, 6.95.
{(1R,2R,5R)-5-tert-Butyl-2-[(6-deoxy-.alpha.-L-galactopyranosyl)oxy]-cyclo-
hex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-gala-
ctopyranoside (E-XI; FIG. 7)
[0238] A mixture of E-X (102 mg, 77.9 .mu.mol), Pd(OH).sub.2/C
(49.4 mg), dioxane (3 mL) and water (0.75 mL) was hydrogenated
under 4 bar at r.t. After 37 h TLC control indicated completion of
the reaction and the mixture was filtered through celite and
evaporated to dryness. The residue was redissolved in methanol (5
mL) and sodium methoxide (0.195 mmol in 255 .mu.L MeOH) was added.
After stirring at r.t. for 14 h the reaction was quenched by
addition of acetic acid (23 .mu.L). The mixture was concentrated in
vacuo and purified by preparative, reversed-phase HPLC to afford
compound E-XI (50.9 mg, 88%) as a white solid.
[0239] [.alpha.].sub.D.sup.21=-93.2 (c=0.91, MeOH); .sup.1H-NMR
(MeOD, .delta.00.1 MHz) .delta.: 0.60-0.77 (m, 5H, H-6.sub.a,
CyCH.sub.2), 0.65 (s, 9H, tBu), 0.84 (m, 1H, H-4.sub.a), 0.93 (m,
1H, CyCH.sub.2), 1.01 (m, 1H, H-5), 1.15 (m, 1H, H-3.sub.a), 1.26
(d, .sup.3J.sub.F5,F6=6.6 Hz, 3H, Fuc H-6), 1.29-1.39 (m, 5H,
CyCH.sub.2), 1.43 (m, 1H, CyCH.sub.2), 1.53 (m, 1H, CyCH.sub.2),
1.60-1.66 (m, 2H, H-4.sub.b, CyCH.sub.2), 1.95 (m, 1H, H-6.sub.b),
2.05 (m, 1H, H-3.sub.b), 3.33 (m, 1H, H-2), 3.56-3.61 (m, 2H, H-1,
Gal H-5), 3.69-3.74 (m, 4H, Fuc H-2, Fuc H-4, Gal H-3, Gal
H-6.sub.a), 3.79 (m, .sup.3J.sub.G6b,G5=6.9 Hz,
.sup.2J.sub.G6a,G6b=11.3 Hz, 1H, Gal H-6.sub.b), 3.91 (dd,
.sup.3J.sub.F3,F4=3.4 Hz, .sup.3J.sub.F2,F3=10.1 Hz, 1H, Fuc H-3),
4.00 (m, 1H, Gal H-4), 4.10 (dd, .sup.3J=2.9, 10.0 Hz, 1H, Lac
H-2), 4.67 (d, .sup.3J.sub.G1,G2=8.0 Hz, 1H, Gal H-1), 4.77 (m, 1H,
Fuc H-5), 4.82 (d, .sup.3J.sub.F1,F2=3.8 Hz, 1H, Fuc H-1), 5.36
(dd, .sup.3J.sub.G1,G2=8.0 Hz, .sup.3J.sub.G2,G3=9.8 Hz, 1H, Gal
H-2), 7.49-7.52 (m, 2H, C.sub.6H.sub.5), 7.61-7.64 (m, 1H,
C.sub.6H.sub.5), 8.10-8.12 (m, 2H, C.sub.6H.sub.5); .sup.13C-NMR
(MeOD, 125.8 MHz) .delta.: 16.53 (Fuc C-6), 25.74 (C-4), 26.60,
26.82, 27.30 (3C, CyCH.sub.2), 27.78 (3C, tBu), 29.73 (C-3), 32.83
(tBu), 33.11 (CyCH.sub.2), 33.74 (C-6), 34.26 (Lac C-4), 35.12
(CyCH.sub.2), 42.76 (Lac C-3), 47.02 (C-5), 62.69 (Gal C-6), 67.38
(Fuc C-5), 67.99 (Gal C-4), 70.03 (Fuc C-2), 71.57 (Fuc C-3), 73.63
(Gal C-2), 73.96 (Fuc C-4), 76.02 (Gal C-5), 76.90 (C-2), 78.03
(Lac C-2), 81.57 (C-1), 83.17 (Gal C-3), 96.51 (Fuc C-1), 101.13
(Gal C-1), 129.74, 130.90, 131.70, 134.40 (6C, C.sub.6H.sub.5),
166.83 (C.dbd.O), 178.78 (COON); HR-MS (ESI) m/z: calcd for
C.sub.38H.sub.58NaO.sub.14[M+H].sup.+: 761.3719; found: 761.3723
(0.5 ppm).
Example 8
{(1R,2R,3S,5R)-2-[(deoxy-.alpha.-L-galactopyranosyl)oxY]-3,5-dimethyl-cycl-
ohex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta.-D-gal-
actopyranoside sodium salt (F-VI; FIG. 8)
[(1R,2R,3S,5R)-1-tert-Butyldimethylsilyloxy-5-hydroxymethyl-3-methyl-cyclo-
hex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyranoside
(F-I)
[0240] To a solution of X (137 mg, 0.191 mmol) in dry THF (2 mL)
was added a solution of 1M LiAlH.sub.4 (667 .mu.L, 0.667 mmol) in
THF at 0.degree. C. under argon over a period of 10 min. After 1 h
the reaction was quenched with satd. aqueous
(NH.sub.4).sub.2SO.sub.4 (0.5 mL) and stirred at r.t. for 1 h. Then
the mixture was dried with Na.sub.2SO.sub.4, filtered and the
solvent evaporated in vacuo. Column chromatography (petroleum
ether/ethyl acetate, 6:1) of the residue gave F-I (110 mg,
84%).
[0241] [.alpha.].sub.D.sup.20=-51.3 (c=0.335, CHCl.sub.3); ESI-MS
m/z: calcd for C.sub.41H.sub.58NaO.sub.7Si [M+Na].sup.+: 713.38;
found: 713.35.
[(1R,2R,3S,5R)-1-tert-Butyldimethylsilyloxy-5-chloromethyl-3-methyl-cycloh-
ex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyranoside
(F-II)
[0242] To a solution of F-I (105 mg, 0.152 mmol) in dry DCE (1.5
mL) under argon 1-chloro-N,N,2-trimethylpropenylamine (43 .mu.L,
0.304 mmol) was added dropwise. After stirring for 45 min at r.t.
the reaction was quenched with MeOH/25% aqueous NH.sub.3 (1:1, 0.5
mL) and evaporated to dryness. Column chromatography (petroleum
ether/ethyl acetate, 19:1) of the residue yielded F-II (91 mg,
85%).
[0243] [.alpha.].sub.D.sup.20=-46.3 (c=2.20, CHCl.sub.3); ESI-MS
m/z: calcd. for C.sub.41H.sub.57ClNaO.sub.6Si [M+Na].sup.+: 731.34;
found 731.42.
[(1R,2R,3S,5R)-1-tert-Butyldimethylsilyloxy-3,5-dimethyl-cyclohex-2-yl]2,3-
,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyranoside (F-III)
[0244] To a solution of F-II (89 mg, 0.125 mmol) and AIBN (21 mg,
0.127 mmol) in dry THF (1.5 mL) was added freshly distilled
Bu.sub.3SnH (366 .mu.L, 1.38 mmol) via a syringe under argon. After
stirring for 90 min at 90.degree. C. the mixture was cooled to r.t.
and diluted in MeCN (5 mL). The solution was washed with hexane (5
mL) and the layers were separated. The hexane layer was washed with
MeCN (2.times.5 mL). The combined MeCN layers were evaporated in
vacuo and the residue purified by column chromatography (petroleum
ether+4% ethyl acetate) to yield F-III (60 mg, 71%).
[0245] [.alpha.].sub.D.sup.20=-43.6 (c=1.28, CHCl.sub.3); ESI-MS
m/z: calcd. for C.sub.41H.sub.58NaO.sub.6Si [M+Na].sup.+: 697.97;
found 697.47.
[(1R,2R,3S,5R)-1-Hydroxy-3,5-dimethyl-cyclohex-2-yl]2,3,4-tris-O-benzyl-6--
deoxy-.alpha.-L-galactopyranoside (F-IV)
[0246] A mixture of F-III (70 mg, 0.104 mmol), THF (1.5 mL), AcOH
(1.8 mL) and H.sub.2O (1.5 mL) was stirred for 4 h at 80.degree. C.
The mixture was cooled to r.t., neutralized with satd. aqueous
NaHCO.sub.3 (approx. 14 mL), diluted with DCM (15 mL) and washed
with water (15 mL). The aqueous layer was then extracted with DCM
(2.times.10 mL). The combined organic layers were dried with
Na.sub.2SO.sub.4, filtered and evaporated to dryness. Column
chromatography (petroleum ether/ethyl acetate, 8:1) of the crude
product gave F-IV (40 mg, 68%).
[0247] [.alpha.].sub.D.sup.20=-40.8 (c=2.00, CHCl.sub.3); ESI-MS
m/z: calcd. for C.sub.35H.sub.44NaO.sub.6 [M+Na].sup.+: 583.30;
found 583.18.
[0248]
{(1R,2R,3S,5R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-.alpha.-L-galactopyr-
anosyl)oxy]-3,5-dimethyl-cyclohex-1-yl}2,4,6-tri-O-benzoyl-3-O-[(1S)-1-ben-
zyloxycarbonyl-2-cyclohexyl-ethyl]-.beta.-D-galactopyranoside
(F-V).
[0249] A mixture of F-IV (45 mg, 80.3 .mu.mol), A-VI (85 mg, 108
.mu.mol) and activated powdered molecular sieves 4 .ANG. (1 g) in
DCM (2 mL) was stirred at r.t. under argon for 4 h. Then a
pre-stirred mixture (4 h, r.t.) of DMTST (83 mg, 0.321 mmol) and
activated powered molecular sieves 4 .ANG. (200 mg) in dry DCM (2
mL) was added. After 24 h the reaction mixture was filtered over
Celite and the filtrate was diluted with DCM (10 mL). The organic
layer was washed with satd. aqueous NaHCO.sub.3 and brine (each 5
mL) and the aqueous layers were extracted with DCM (2.times.5 ml).
The combined organic layers were dried with Na.sub.2SO.sub.4,
filtered and evaporated to dryness. The residue was purified by
column chromatography on silica gel (petroleum ether/ethyl acetate,
6:1) to yield F-V (63 mg, 62%).
[0250] [.alpha.].sub.D.sup.20=-47.0 (c=2.17, CHCl.sub.3); ESI-MS
m/z: calcd. for C.sub.78H.sub.86NaO.sub.16 [M+Na].sup.+: 1301.58;
found 1301.64.
[0251]
{(1R,2R,3S,5R)-2-[(deoxy-.alpha.-L-galactopyranosyl)oxy]-3,5-dimeth-
yl-cyclohex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-.beta-
.-D-galactopyra noside sodium salt (F-VI; FIG. 8).
[0252] A mixture of F-V (50 mg, 39.1 .mu.mol), Pd(OH).sub.2/C (27
mg, 10% Pd), dioxane (1.5 mL) and water (400 .mu.L) was
hydrogenated in a Parr-shaker at 5 bar. After 4 h the mixture was
filtered over Celite and evaporated to dryness. The residue was
re-dissolved in MeOH (3 mL) and NaOMe (97.8 .mu.mol in 160 .mu.L
MeOH) was added. After stirring at r.t. for 16 h the reaction was
quenched with AcOH (10 .mu.L), concentrated in vacuo and purified
by preparative, reversed-phase HPLC. The freeze-dried product was
re-dissolved in water and one equivalent of NaOH was added. The
solution was lyophilized from water to afford F-VI (23.3 mg, 80%)
as a white solid.
[0253] [.alpha.].sub.D.sup.20=-89.0 (c=1.16, H.sub.2O); ESI-MS m/z:
calcd. for C.sub.36H.sub.54NaO.sub.14 [M+H].sup.+: 733.34; found
733.41.
Example 9
Synthesis of Pegylated Mimic (FIG. 10)
Synthesis of Second Compound of FIG. 10
[0254] First compound (100 mg) of FIG. 10 was mixed with
ethylenediamine under the argon. The resulting mixture was heated
at 70.degree. C. for 7 hr. After evaporation, the residue was
purified on C-18 column to afford 55 mg second compound. Yield
68%
PEGylation of Second Compound of FIG. 10
[0255] Second compound (5 mg) was mixed with
mPEG-nitrophenylcarbonate (5K) 75 mg, triethylamine 5 ul in DMF (2
mL). The resulting mixture was stirred at rt for 3 h. The solvent
was removed at reduced pressure. The residue was purified on C-18
to afford 40 mg product.
Example 10
Synthesis of Tetramer Pegylated Mimic (FIG. 11)
[0256] Second compound (20 mg) from Example 9 was mixed with 200 mg
4-arm PEG glutamidylsuccinate, triethylamine 5 ul and DMF 2 mL. The
resulting mixture was stirred at rt for 2 hr. After removing the
solvent, the residue was purified on HPLC to afford the
product.
Example 11
Synthesis of Compound G-IV (FIG. 12)
[0257] Synthesis of intermediate G-II: Compound XXII (100 mg;
Example 2) was treated with 0.01N NaOEt in EtOH (2 ml) 2 h at room
temperature, neutralized with AcOH and the solution was evaporated
to dryness. The residue was purified by column chromatography to
give G-II (47 mg).
[0258] Synthesis of intermediate G-III: Compound G-II (250 mg) was
dissolved in dioxane-water (10:1, 6.6 ml) and treated with 10% Pd/C
under atmosphere of hydrogen for overnight. Solid was filtered off
and filtrate was evaporated to dryness. The residue was purified by
column chromatography (silica gel) to give compound G-III (100
mg).
[0259] Synthesis of compound G-IV: NH.sub.2OH. HCl (64 mg) was
dissolved in H.sub.2O (0.5 ml). To this solution was added a
solution of NaOH (70 mg) in H.sub.2O (0.5 ml). Compound G-III (25
mg) in MeOH (0.5 ml) was added to the above solution with stirring
at room temperature. The mixture was stirred at room temperature
for 15 min and then neutralized to pH 7.0 by adding 1N HCl
solution. Solvent was evaporated off and the residue was purified
by column chromatography (silica gel) to give compound G-IV.
Example 12
Synthesis of Compound H-IV (FIG. 13)
[0260] Synthesis of intermediate H-II: Compound F-V (100 mg;
Example 8) was treated with 0.01N NaOEt in EtOH (2 ml) 2 h at room
temperature, neutralized with AcOH and the solution was evaporated
to dryness. The residue was purified by column chromatography to
give H-II (55 mg).
[0261] Synthesis of intermediate H-III: Compound H-II (125 mg) was
dissolved in dioxane-water (10:1, 6.6 ml) and treated with 10% Pd/C
under atmosphere of hydrogen for overnight. Solid was filtered off
and filtrate was evaporated to dryness. The residue was purified by
column chromatography (silica gel) to give compound HAI (75
mg).
[0262] Synthesis of compound H-IV: Compound HAI is treated in the
same way as described for the synthesis of G-IV to give H-IV.
Example 13
Sickle Cell Mice
[0263] FIG. 14 provides the timeline used for studying the effects
of an oligosaccharide mimic ("test compound"--see FIG. 14 for
chemical structure) on microvascular flow in sickle cell mice.
Microvascular flow was determined by intravital microscopy.
[0264] FIG. 15 shows the effects of test compound on the number of
immobilized leukocytes on the endothelium in sickle cell mice
during stimulation in vivo. Vehicle alone was used as the control.
The data is based on 7 mice/cohort for control, and 4 mice/cohort
for the test compound cohort. Measurements were taken at between
about 20 to 30 locations for each mouse.
[0265] FIG. 16 shows the effects of test compound on adherence of
SSRBCs to leukocytes in sickle cell mice during stimulation in
vivo. Control and mice/cohort were the same as described above for
FIG. 15.
[0266] FIG. 17 shows the effects of a test compound on the time of
survival of sickle cell mice after induction of a vaso-occlusive
crisis by administration of TN Fa.
Example 14
Endothelial Stimulation
[0267] Glycated serum proteins induce neutrophil rolling on
endothelial cells in an in vitro assay of cell adhesion under flow
conditions. Monolayers of human umbilical vein endothelial cells
(HUVECS) were incubated in glycated serum proteins (FIG. 18,
glycated albumin, Gly-HSA or FIG. 19, glycated hemoglobin, Gly-Hb)
for 4 hours. Monolayers were then inserted into a flow chamber and
the chamber was perfused with human neutrophils (10.sup.6 cell/ml)
at a flow rate corresponding to a wall shear stress of 0.9
dynes/cm.sup.2. Digital images were acquired and analyzed to
determine the rolling index (RI) which is a measure of the degree
of neutrophil rolling on the endothelial cell monolayer. Glycated
HSA yielded about a 6-fold increase in rolling while glycated
hemoglobin yielded approximately a 2.8-fold increase. The effects
of the addition of test compound to the perfused neutrophils is
shown in FIG. 20. At 50 .mu.M, about 90% of the cell rolling is
inhibited by the test compound. As the test compound is a highly
specific and potent inhibitor of E-selectin, the increased rolling
of neutrophils induced by glycated serum proteins is mainly due to
expression of E-selectin.
Example 15
Diabetic Mice
[0268] Normal C57BL/6 mice and diabetic (db/db) C57BL/6 mice were
used. Diabetic (db/db) mice contain a mutation in the leptin
receptor resulting in uncontrolled hunger and obesity, leading to
hyperglycemia and diabetes. Leukocyte rolling was measured by
intravital microscopy. As shown in FIG. 21, diabetic mice (db/db)
display a 4- to 5-fold increased leukocyte rolling over normal mice
(C57BL/6).
[0269] FIG. 21 shows the percent inhibition of leukocyte rolling in
diabetic (db/db) mice by test compound relative to vehicle control.
Clearly the test compound has an immediate effect of inhibiting
cell flux which lasts throughout the length of the experiment.
[0270] All of the above U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, foreign
patent applications and non-patent publications referred to in this
specification and/or listed in the Application Data Sheet, are
incorporated herein by reference, in their entirety.
[0271] From the foregoing it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
* * * * *